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Summary  
Lymphoma (LSA) is a malignant neoplasm which arises from a clonal proliferation of 
lymphoreticular cells (Vail et al., 2013). It is the most common canine haematopoietic 
neoplasm (Gavazza et al., 2009; Vail et al., 2013), and accounts for 7-24% of all canine 
malignancies (Greenlee et al., 1990; Dobson et al., 2002; Fournel-Fleury et al., 2002). 
Multiple blood and tissue biomarkers have been investigated regarding potential 
prognostic significance for canine LSA, however currently there is no single marker 
which has proven to be more reliable than the established parameters such as substage, 
immunophenotype and grade.  
Clusterin (CLU), also known as apolipoprotein J, is a heterodimeric glycoprotein which 
is widely expressed (Trougakos et al., 2002, 2004) throughout the body. CLU is important 
in tumorigenesis, apoptosis, and immunoregulation (Trougakos et al., 2002; Pucci et al., 
2004; Shannan et al., 2006); its expression is regulated by cytokines and growth factors, 
and is increased in response to physiological stress (Trougakos et al., 2002, 2004; 
Shannan et al., 2006).  In human medicine, CLU expression has been associated with 
various malignancies, including carcinoma, melanoma, colon, prostate and breast cancer 
(Saffer et al., 2002; Pucci et al., 2004; Shannan et al., 2006; Frazzi et al., 2011; Koltai, 
2014). Cytoplasmic expression of CLU is also upregulated in cases of anaplastic large 
cell lymphoma and Hodgkin's lymphoma (HL) (Wellmann et al., 2000; Saffer et al., 
2002; Shannan et al., 2006; Frazzi et al., 2011).   
A previous study of the canine serum proteome identified CLU in serum from a dog with 
high grade multicentric lymphoma (MLSA), and the absence of CLU in serum from  
healthy controls (Atherton et al., 2013a, 2013b). The objective of this current study was 
to determine whether CLU expression differed significantly between those dogs with 
MLSA and a healthy control population. It was hypothesised that serum CLU expression 
would be higher in dogs with MLSA in comparison to healthy controls and that serum 
CLU levels would subsequently decrease in affected animals, where clinical remission 
had been achieved following successful treatment.  
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In the current study, serum CLU levels in dogs with MLSA were compared to healthy 
control dogs using both western blot and enzyme linked immunosorbent assay (ELISA). 
The presence of CLU in dog sera was confirmed by western blot analysis, detected at the 
predicted molecular weight, and the relative levels detected via western blot correlated 
with those detected by ELISA. Serum CLU analysis by ELISA found treatment naïve 
dogs with MLSA had a significantly (p<0.001) lower serum CLU level in comparison to 
healthy controls. There was no significant difference in serum CLU concentrations 
between MLSA dogs prior to treatment and those in complete remission (CR).  
Serum CLU concentrations showed wide variation across all canine samples, limiting the 
potential as a single candidate biomarker for MLSA. The potential for any prognostic 
predictive value of serum CLU concentrations has yet to be assessed. 
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1 Introduction 
1.1 Lymphoma 
Lymphoma (LSA) is a malignant neoplasm which arises from a clonal proliferation of 
lymphoreticular cells (Vail et al., 2013). It is the most common canine haematopoietic 
neoplasm (Gavazza et al., 2009; Vail et al., 2013), and the third most common canine 
neoplasm (Greenlee et al., 1990), accounting for 7-24% of all canine malignancies 
(Greenlee et al., 1990; Dobson et al., 2002; Fournel-Fleury et al., 2002). Although usually 
occurring in lymphoid organs, including the lymph nodes, spleen and bone marrow, LSA 
can occur in any tissue in the body (Vail et al., 2013).  
 
 Classification  
Classification of canine LSA is based primarily on anatomical location, histological 
criteria and immunophenotypic characteristics (Vail et al., 2013).  
 Anatomical  
Multicentric lymphoma (MLSA) is the most common anatomical form of canine LSA, 
accounting for around 84% of all cases (Vail et al., 2013, 2019), and primarily affecting 
the peripheral lymph nodes. Gastrointestinal lymphoma accounts for a further 5-7% of 
canine LSA diagnosis (Couto et al., 1989; Vail et al., 2013), and is the most common 
presentation of extranodal lymphoma, occurring as both focal and diffuse changes within 
the gastrointestinal tract. Mediastinal lymphoma accounts for approximately 5% of 
canine LSA (Rosenberg et al., 1991; Vail et al., 2019) with cutaneous lymphoma also 
noted with similar frequency (Moore et al., 2009; Fontaine et al., 2010; Vail et al., 2019). 
Primary hepatosplenic (Fry et al., 2003; Cienava et al., 2004; Keller et al., 2012), 
pulmonary (Berry et al., 1990; Fitzgerald et al., 1991), prostatic (Mainwaring, 1990; 
Winter et al., 2006; Donato et al., 2019), ocular and central nervous system (CNS) (Rosin, 
1982; Couto et al., 1984; Kim et al., 2012; Siso et al., 2016) LSA are less commonly 
reported forms of extranodal lymphoma.  
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 Morphological  
Canine LSA can be classified as high grade (HG), intermediate grade, or low 
grade/indolent (LG), depending on histology and morphological cellular characteristics.  
Large, immature cells, high mitotic rate, rapid progression and considerable malignant 
potential are features of HG LSA, with LG LSA exhibiting, a slow rate of growth, and 
smaller, more mature cells, with a low mitotic rate. Canine MLSA usually presents as 
diffuse and HG (Flood-Knapik et al., 2013), with LG LSA less common, accounting for 
less than 30% of diagnosed cases (Teske et al., 1994b, 1996; Fournel-Fleury et al., 1997; 
Vail et al., 2013).   
 Immunophenotype  
At the cellular level, LSA arises from clonal proliferation of lymphoid cells, of B-cell or 
T-cell lineage (Vail et al., 2013). Canine LSA most commonly arises from the B-cell 
lineage, with T cell LSA accounting for only around 30% of cases (Teske et al., 1994b; 
Fournel-Fleury et al., 1997, 2002; Modiano et al., 2005; Valli et al., 2013). 
Immunophenotyping is essential for an accurate diagnosis of LSA subtypes and is a 
fundamental part of LSA classification. Additionally, immunophenotype can be of 
prognostic value and alter treatment planning (Regan et al., 2013; Vail et al., 2019).  
Immunohistochemistry and immunocytochemistry (IHC/ICC) determine 
immunophenotype by detection of cell surface antigens on cytology or histology 
specimens, utilizing antibodies against specific lymphocyte markers. Flow cytometry 
uses analysis of light scatter and fluorescence of cells in a fluid suspension in order to 
categorise cells via surface antigen expression, and size (Culmsee et al., 2001). 
Antibodies against cell surface markers are utilised and cell heterogeneity assessed to 
determine lineage (Sözmen et al., 2005; Tasca et al., 2009; Comazzi et al., 2011). 
Molecules specific to B-lymphocytes include CD79a, CD20, CD21 and Pax5. Those 
specific to T-cells include CD3, CD4, and CD8, although some aberrant expression of 
markers has been documented in lymphoid malignancies (Wilkerson et al., 2005; Seelig 
et al., 2016; Vail et al., 2019). Lymphomas which express neither CD3 nor CD79a are 
termed null cell lymphoma. These are rare, accounting for less than 1% of canine 
diagnoses (Ponce et al., 2010).  
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Polymerase chain reaction (PCR) for antigen receptor rearrangement (PARR) analysis 
detects lymphocyte antigen rearrangement at the DNA level, and thus determines B-cell 
and T-cell immunophenotype using specific primers for the T-cell receptor or B-cell 
immunoglobulin region (Keller et al., 2016; Vail et al., 2019). Immunophenotyping can 
be performed via PARR analysis (Thalheim et al., 2013; Waugh et al., 2016; Ehrhart et 
al., 2019), with a high specificity (Thalheim et al., 2013) and accuracy (Ehrhart et al., 
2019). While highly specific for determining immunophenotype, PARR is deemed 
inferior to flow cytometry due to a lower sensitivity, particularly for diagnosis of B-cell 
lymphoma (Thalheim et al., 2013; Ehrhart et al., 2019), although this can vary with 
different primer sets (Waugh et al., 2016). 
 Subtype 
Many classification systems for human Non-Hodgkin’s lymphoma (NHL) have been 
described and adapted for canine LSA (Vail et al., 2013, 2019), with the Revised 
European American Lymphoma (REAL) and World Health Organisation (WHO) systems 
the current accepted method of histological classification. These assess anatomic location, 
nodal architecture, cell morphology and immunophenotype to allow classification of 
specific LSA subtypes, with the aim of better understanding disease behaviour and 
progression (Vezzali et al., 2010; Vail et al., 2019). Nearly 50 individual subtypes of 
human NHL have been described, with many advocating to consider lymphoma a group 
of diseases rather than one distinct entity (Vail et al., 2019). Using the WHO guidelines, 
20 different canine subtypes have been identified (Seelig et al., 2016). Based on these 
guidelines the majority of canine LSA can be classified into one of five subtypes; diffuse 
large B-cell lymphoma (DLBCL), the most common canine subtype, marginal zone 
lymphoma, peripheral T-cell lymphoma not otherwise specified, nodal T-zone lymphoma 
and T lymphoblastic lymphoma (Valli et al., 2011; Seelig et al., 2016).  
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  Clinical Presentation of multicentric lymphoma 
 Signalment 
LSA commonly occurs in older animals (Edwards et al., 2003), with over 90% of  cases 
diagnosed in dogs >5years old (Modiano et al., 2005). The majority of dogs are middle 
aged at time of diagnosis, with a median age of 6 to 9 years (Teske, 1994; Edwards et al., 
2003; Modiano et al., 2005). Prevalence varies between dog breeds, with certain breeds, 
particularly boxer dogs, bulldogs and bullmastiffs reported to have a high prevalence of 
lymphoproliferative disease (Teske, 1994; Teske et al., 1994a; Edwards et al., 2003; 
Modiano et al., 2005; Villamil et al., 2009; Vail et al., 2013). Breeds with a lower relative 
risk include the dachshund, Pomeranian (Teske, 1994; Teske et al., 1994a; Vail et al., 
2013) and Chihuahua (Modiano et al., 2005). More recently LSA has been linked to body 
weight, with dogs >30kg having increased odds of diagnosis (Pittaway et al., 2019). 
Gender and neutering status were previously not thought to affect prevalence (Edwards 
et al., 2003; Modiano et al., 2005). However recent reports indicate entire females at 
significantly lower risk (Villamil et al., 2009; Vail et al., 2013; Pittaway et al., 2019), and 
neutered dogs at increased risk (Pittaway et al., 2019), potentially indicating a protective 
hormonal component to the disease.  
 Stage 
MLSA is grouped into stages based on the extent of lymph node or lymphoid tissue 
involvement. These stages are numbered I -V. 
Clinical Stages of canine MLSA  
I - Involvement limited to a single node or lymphoid tissue in a single organ, 
excluding bone marrow. 
II - Involvement of many lymph nodes in a regional area, including tonsils. 
III - Generalized lymph node involvement.  
IV - Liver and/or spleen involvement, in addition to Stage III. 
V - Manifestation in the blood and involvement of bone marrow and/or other 
organ systems, in addition to Stages I-IV. 
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 Substage 
Each MLSA stage is further classified into substage a or b, depending on the presence or 
absence of clinical signs (Owen, 1980), with substage b indicating the presence of 
concurrent, systemic signs e.g. diarrhoea, dyspnoea, hypercalcaemia (Owen, 1980; Vail 
et al., 2013).  The majority of dogs present with lymphadenopathy but are otherwise 
clinically well, i.e. substage a (Vail et al., 2013). Dogs presented with T-cell LSA are 
more likely to present in substage b (Vail et al., 2013) with clinical signs related to the 
anatomical location of their tumour burden, or concurrent paraneoplastic syndromes.  
 Presenting signs  
Dogs typically present with a non-painful, peripheral lymphadenopathy (Greenlee et al., 
1990; Baskin et al., 2000; Vail et al., 2013), although clinical signs can vary with organs 
affected and extent of disease (Teske, 1994; Teske et al., 1994a; Gavazza et al., 2009; 
Vail et al., 2013). Most dogs with MLSA, present with advanced disease, stages III-V 
(Greenlee et al., 1990; Dobson et al., 2001) but in substage a (Vail et al., 2013). With 
progression of disease, different clinical signs can occur, including anorexia, weight loss, 
gastrointestinal signs, or signs relating to organ failure (Baskin et al., 2000; Vail et al., 
2013). In addition dogs may present with, or develop, signs related to bone marrow 
infiltration, including anaemia, haemorrhage or infection secondary to pancytopenia (Vail 
et al., 2013).  
Paraneoplastic syndromes are frequently associated with canine LSA, with anaemia the 
most common, occurring in 30-43% (Madewell et al., 1980; Abbo et al., 2007; Miller et 
al., 2009; Childress et al., 2018; Bailey, 2019; Vail et al., 2019). Other haematological 
disturbances (e.g. polycythaemia, eosinophilia) are less common but occur, particularly 
with T-cell LSA (Ozaki et al., 2006; Tomiyasu et al., 2010; Durno et al., 2011; McNaught 
et al., 2018; Vail et al., 2019). Hypercalcaemia is also frequently seen, most commonly, 
although not exclusively, associated with T-cell LSA (Greenlee et al., 1990; Rosenberg 
et al., 1991; Bergman, 2012; Zandvliet, 2016; Bailey, 2019). Less common 
paraneoplastic syndromes include hypoglycaemia (Zhao et al., 1993) 
hyperglobulinaemia/monoclonal gammopathies (Giraudel et al., 2002; Tappin et al., 
2011; Bailey, 2019) and immune mediated diseases (e.g. immune mediated haemolytic 
anaemia, immune mediated thrombocytopenia (Keller, 1992), polymyositis (Evans et al., 
2004)). 
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 Diagnosis  
Diagnosis of MLSA, regardless of anatomic location or presenting signs, is made via   
morphological examination of neoplastic tissue and/or cells. 
Cytology is frequently used for the diagnosis of canine LSA using morphological features 
of cells (Fournel-Fleury et al., 2002; Sözmen et al., 2005; Vail et al., 2013). Cytology 
samples can also be used to determine immunophenotype, by applying suitable B and T 
cell antibodies. Misdiagnosis through cytology is possible and severe, reactive 
hyperplasia may be difficult to differentiate from LSA through cytology alone. In addition 
some LG small cell LSA may have subtle features of malignancy, making definitive 
diagnosis more difficult (Vail et al., 2013).  
Histology provides more information than cytology, as evaluation of nodal architecture 
and pattern of nodal infiltration, allows classification of LSA as either nodular, follicular 
or diffuse (Carter et al., 1986; Seelig et al., 2016). The majority of canine MLSA exhibit 
a diffuse pattern of proliferation, with neoplastic lymphocytes causing complete 
effacement of the normal nodal structure, often with capsular disruption (Carter et al., 
1986; Fournel-Fleury et al., 1997; Valli et al., 2011; Flood-Knapik et al., 2013; Vail et 
al., 2013). Histopathology of an entire lymph node is preferable for diagnosis and 
classification (Vail et al., 2013). Based on histology characteristics numerous 
classification schemes to accurately categorise canine LSA have been reported, see 
section 1.1.1.4. 
A complete diagnostic work up for MLSA usually involves physical examination, 
complete blood count, biochemistry profile and urinalysis. Thoracic and abdominal 
imaging, examination of peripheral blood smear and bone marrow sampling, are also 
usually performed to establish the extent of disease/clinical stage. 
 Molecular diagnostics 
As lymphoid neoplasia derives from a clonal expansion of lymphocytes, the identification 
of a homogenous, monomorphic or clonal population of lymphoid cells supports a 
diagnosis of LSA. 
 
7 
 
Lymphocytes each have unique T-cell receptor and immunoglobulin genes, determined 
through recombination of variable gene regions, to encode for specific antigen-binding 
sites (Keller et al., 2016; Vail et al., 2019). Lack of variation of these specific 
complementarity-determining (CDR3) regions can be evaluated as marker of malignancy 
in a lymphoid population (Burnett et al., 2003; Gentilini et al., 2009; Waugh et al., 2016). 
Clonality can be determined by isolating lymphoid DNA and using targeted PCR primers 
to amplify the individual variable regions (Avery, 2009). The PARR clonality assay is 
valuable diagnostic tool, and can be used in a variety of sample types, with high diagnostic 
accuracy (Ehrhart et al., 2019). 
Complete and thorough diagnosis of lymphoid neoplasia often requires ancillary testing 
and determination of immunophenotype, via immunohistochemistry/cytochemistry 
and/or flow cytometry, see section 1.1.1.3. 
 
 Treatment  
Chemotherapy is the treatment of choice for MLSA, as it is considered a systemic disease. 
Current treatment aims to induce remission and prolong survival, and will rarely provide 
a clinical cure (Marconato, 2011; Vail et al., 2013; Thamm, 2019). Multiagent 
chemotherapy is generally considered the most efficacious with regard to overall survival 
time (OST) and progression free survival (PFS) (Vail et al., 2019). CHOP-based 
chemotherapy protocols are widely used, with cyclophosphamide (C ), vincristine (O), 
doxorubicin (H) and prednisolone (P) given cyclically over 12-25 weeks (Keller et al., 
1993; Moore et al., 2001; Simon et al., 2006; Burton et al., 2013; Curran et al., 2015). 
The benefit of ongoing/maintenance treatment, following an initial chemotherapy course, 
has not been proven, and is rarely used (Chun et al., 2000; Moore et al., 2001; Garrett et 
al., 2002; Simon et al., 2008; Vail et al., 2019). Multiagent CHOP-based protocols induce 
remission in 80-95% of cases, with median survival time (MST) of 10-12 months (Vail 
et al., 2019) although 20% of patient may achieve survival times >2 years (Chun et al., 
2000; Garrett et al., 2002; Burton et al., 2013; Curran et al., 2015; Thamm, 2019).  
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Single agent protocols, with the exception of doxorubicin, are used less frequently and do 
not result in significant or durable remission (Carter et al., 1987; Mutsaers et al., 2002; 
Lori et al., 2010; Thamm, 2019; Vail et al., 2019). Immunophenotype may dictate 
treatment, with T-cell MLSA responding less favourably to CHOP-based protocols 
(Beaver et al., 2010), and the addition of alkylating agents thought to confer a survival 
advantage (Brodsky et al., 2009; Goodman et al., 2016; Moore, 2016; Brown et al., 2018; 
Elliott et al., 2019). Oral corticosteroids, have direct cytotoxic activity (Smith et al., 
2010), and when used as a sole treatment will frequently induce at least partial remission 
(PR), although disease free interval (DFI) is short (Thamm, 2019).  
Other therapeutic options are used less frequently and may only be applicable to 
individual subtypes of LSA. Different treatment options may be appropriate for solitary 
or focal disease, and LG LSA, which may respond more favourably to less intensive 
therapy (Flood-Knapik et al., 2013; Moore, 2016). 
Lymphoid cells are radiosensitive and radiation therapy (RT) has been used both as a sole 
treatment and in combination with chemotherapy (Gustafson et al., 2004; Williams et al., 
2004; Mayer et al., 2005; Vaughan et al., 2007; Lurie et al., 2009), in naïve and relapsed 
LSA. As a systemic disease the indication for RT in the treatment of LSA is limited and 
the lack of evidence supporting a superior clinical outcome limits the use of RT for MLSA 
in clinical practice (Thamm, 2019; Vail et al., 2019). 
Immunomodulatory therapies have also been proposed as adjuvant treatment options for 
canine LSA. Various canine specific monoclonal antibodies, targeting both B and T-cells, 
have been evaluated (Impellizeri et al., 2006; Rue et al., 2015; Regan et al., 2016; 
Weiskopf et al., 2016; Klingemann, 2018; Thamm, 2019; Vail et al., 2019). Several 
autologous and DNA vaccines have also been trialled, with reports suggesting improved 
outcome for indolent and HG B-cell LSA (Jeglum et al., 1986, 1988; Turek et al., 2007; 
Peruzzi et al., 2010; Gavazza et al., 2013; Marconato et al., 2014, 2015a, 2019). 
Regardless of modality or adjunct therapies, treatment is rarely curative. However, with 
appropriate therapy, complete clinical remission and extension of good quality life can be 
expected. 
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 Response to treatment  
Monitoring response to treatment can be subjective, through lymph node palpation, or 
objective, through lymph node measurement or biological detection of minimal residual 
disease (MRD). Standardisation of treatment response has been described (Vail et al., 
2010), recommending routine measurement of between one and five target lesions/lymph 
nodes, with response defined by the response evaluation criteria in solid tumours 
(RECIST) guidelines as: 
- Complete remission (CR), no evidence of disease, all lymph nodes non-
pathologic in size.  
- Partial remission (PR), at least a 30% decrease in target lesions, but not 
complete resolution.  
- Stable disease (SD), no significant increase or decrease in target lesions. 
- Progressive disease (PD), at least a 20% increase in target lesions, and/or 
unequivocal progression of existing non-target lesions/the appearance of one or 
more new lesions.   
Defining overall response takes into consideration target, non-target and new lesions. 
Accurate monitoring of response to treatment can aid detection of early relapse, or lack 
of response, allowing alterations to the treatment protocol.  
Definition and measurement of duration of response has also been standardised, to ensure 
a consensus for temporal response measurements, with common definitions defined 
below:  
- Median survival time (MST), measured from diagnosis or initiation of 
treatment to death, of 50% of the measured cohort.  
- Overall survival time (OST), measured from initiation of treatment to death, 
from any cause. 
- Lymphoma specific survival (LSS), measured from initiation of treatment, to 
disease progression or death, from LSA only.  
- Disease-free interval (DFI), assesses only those patients in CR, measured from 
documentation of response, to time of relapse, or death. 
- Progression-free survival (PFS), measured from initiation of treatment, to 
disease progression or death, from any cause.  
As treatment for LSA is rarely curative and factors including owner finance and perceived 
quality of life can influence decisions for euthanasia, the preferred measurement of 
response is PFS (Vail et al., 2010).  
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 Prognosis 
Prognosis for canine MLSA can be variable, due to the heterogeneity of the disease, and 
multiple factors can impact prognosis, both positively and negatively. Treatment with 
chemotherapy significantly improves prognosis, and survival time, when compared to no 
treatment, or treatment with corticosteroids only (Vail et al., 2019). Additionally, 
response to treatment can be highly prognostic (Dobson et al., 2001; Edwards et al., 
2003). The main prognostic factors are discussed below. 
 Signalment  
Prevalence of LSA can be strongly linked to signalment, and many factors have been 
investigated regarding prognostic significance. While LSA is most common in older 
patients, age at diagnosis was not found to be independently prognostic (Greenlee et al., 
1990; Teske et al., 1994c; Kiupel et al., 1999; Dobson et al., 2001; Jagielski et al., 2002; 
Gavazza et al., 2009). Numerous studies have linked prognosis to gender, with varied 
results. Both male (Siedlecki et al., 2006; Zandvliet, 2016) and female (Keller et al., 1993; 
Vail et al., 2019) gender and neuter status, have been linked with an unfavourable 
prognosis, while other studies have indicated no prognostic association with sex or neuter 
status (Greenlee et al., 1990; Teske et al., 1994c; Kiupel et al., 1999; Dobson et al., 2001; 
Jagielski et al., 2002; Gavazza et al., 2009). Many breeds appear predisposed to LSA, 
however strong prognostic association with individual breeds has not been documented. 
Small-breed dogs may have a more favourable prognosis than large-breed (Zandvliet, 
2016), with one study suggesting dogs weighing <18kg achieved longer DFI and OST 
(Garrett et al., 2002). An unrelated study also linked body condition score to survival, 
with dogs underweight at time of diagnosis having shorter survival times (Romano et al., 
2016). The majority however, indicate no association between weight or breed, achieving 
remission, OST or DFI (Appelbaum et al., 1984; Teske et al., 1994c; Kiupel et al., 1999; 
Dobson et al., 2001). Overall, due to highly variable results, the prognostic significance 
of signalment appears minimal.  
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 Presenting signs  
The presence of clinical signs at diagnosis (WHO substage b (Owen, 1980)) has been 
consistently linked to poorer prognosis (Greenlee et al., 1990; Hahn et al., 1992; Keller 
et al., 1993; Baskin et al., 2000; Jagielski et al., 2002; Romano et al., 2016; Vail et al., 
2019), with clinical signs secondary to hypercalcaemia of malignancy often conferring a 
poorer prognosis (Greenlee et al., 1990; Rosenberg et al., 1991; Keller et al., 1993; 
Marconato et al., 2011).    
Haematological abnormalities, particularly anaemia and thrombocytopenia at 
presentation, are negative prognostic indicators (Davies et al., 2018; Vail et al., 2019) 
associated with shorter OST (Abbo et al., 2007; Miller et al., 2009; Burton et al., 2013; 
Romano et al., 2016; Purzycka et al., 2020), shorter PFS (Zemann et al., 1998; Moore et 
al., 2001; Burton et al., 2013; Childress et al., 2018; Davies et al., 2018), and increased 
risk of incomplete remission (Childress et al., 2018). Monocytosis and neutrophilia are 
also indicators of poor prognosis (Perry et al., 2010; Childress et al., 2018; Vail et al., 
2019; Purzycka et al., 2020).  
In addition to clinical signs and haematological abnormalities, prior treatment with 
steroids is a negative prognostic factor, with an unfavourable effect on survival time and 
poorer response to treatment (Price et al., 1991; Dobson et al., 1994; Gavazza et al., 2009; 
Marconato et al., 2011). 
Anatomic location is also prognostic, with extra nodal LSA carrying a less favourable 
prognosis, and cutaneous, hepatosplenic, HG gastrointestinal and CNS LSA all 
individually associated with a poor prognosis (Vail et al., 2019). Additionally, the 
presence of mediastinal lymphadenopathy was a negative prognostic factor for DFI and 
MST (Starrak et al., 1997) in MLSA.   
 Classification  
Prognosis for canine MLSA is strongly linked to classification, with clinical stage, 
histopathological grade and immunophenotype all holding varying degrees of prognostic 
significance.  
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Immunophenotype consistently holds prognostic significance for MLSA, with 
intermediate-high grade T-cell LSA responding less favourably to chemotherapy 
(Greenlee et al., 1990; Beaver et al., 2010) often with incomplete remission, shortened 
remission and survival times (Greenlee et al., 1990; Teske et al., 1994c; Kiupel et al., 
1999; Dobson et al., 2001; Edwards et al., 2003; Ponce et al., 2004; Marconato et al., 
2011; Mutz et al., 2013). The exception is T-zone LSA, which is typically low grade and 
confers a more favourable prognosis (Valli et al., 2013; Avery et al., 2014; Seelig et al., 
2014). Histological grade of malignancy is a reliable prognostic factor (Teske et al., 
1994c; Dobson et al., 2001; Marconato et al., 2011; Vail et al., 2019), with intermediate 
and HG LSA tending to respond well to chemotherapy initially, but suffering early 
relapse, with OST poor. In comparison LG/indolent LSA is often associated with 
prolonged survival (Valli et al., 2006, 2013; Flood-Knapik et al., 2013; Vail et al., 2019). 
Various classification systems including the Kiel and National Cancer Institute Working 
Formulation show prognostic significance (Hahn et al., 1992; Teske et al., 1994c). 
Clinical stage, as determined by the WHO staging system (Owen, 1980), has been shown 
to hold prognostic significance, with higher stage associated with poor prognosis (Price 
et al., 1991; Dobson et al., 1994; Teske et al., 1994c; Jagielski et al., 2002; Marconato et 
al., 2011). However a similar number of studies have shown no prognostic association 
with disease stage (Greenlee et al., 1990; Rosenberg et al., 1991; Hahn et al., 1992; 
Kiupel et al., 1999; Dobson et al., 2001). This may, in part, be due to variation in 
diagnostic work/investigations carried out, either under or over-estimating the 
extent/stage of disease. Stage migration, due to the absence of imaging and 
cytological/histological confirmation of organ involvement, could render many accounts 
of clinical stage inaccurate.  
 Proliferation markers  
Markers of proliferation also hold prognostic significance. Proliferation indices, 
including proliferating cell nuclear antigen (PCNA), Ki-67 staining and argyrophilic 
nucleolar organiser regions (AgNOR) are elevated in canine LSA (Hipple et al., 2003; 
Bauer et al., 2007). AgNOR and Ki-67 correlate with histological grade (Poggi et al., 
2015), and are prognostic for OST and DFI (Kiupel et al., 1998; Kiupel, 1999; Poggi et 
al., 2017).   
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 Biomarkers 
A biomarker is a substance, structure or process which can be measured to provide 
information regarding a biological condition or state, with medical biomarkers providing 
diagnostic or prognostic information, or information predicting response to therapy 
(Strimbu et al., 2010; Chen et al., 2011; Nalejska et al., 2014; Bryan, 2016). Biomarkers 
should be objective, quantifiable and repeatable, as well as specific for the biological 
process of interest. Classified based on their function, biomarkers can be used to predict 
disease risk, act as diagnostic tools, at a clinical or subclinical level, or used to categorise 
disease severity, forecast future progression, and predict response to treatment or relapse 
(Srivastava et al., 2002; Chen et al., 2011). The most useful biomarkers have a high 
predictive accuracy, are easy to measure, non-invasive and reproducible (Srivastava et 
al., 2002; Chen et al., 2011). 
Biomarkers measured in biological media, such as tissues, cells or fluid, have become 
widely used in the medical profession over the past few decades, for early disease 
detection, to monitor response to treatment, and also as a surrogate end point in clinical 
trials (Srivastava et al., 2002; Strimbu et al., 2010; Chen et al., 2011). In comparison to 
other areas, biomarker use in neoplasia is relatively limited (Johann et al., 2007) and, 
given the inherent heterogeneity of the population, and of individual tumours, panels of 
biomarkers are often preferred, giving greater insight than single markers alone (Johann 
et al., 2007; Chen et al., 2011). Biomarkers are particularly useful in human neoplasia, 
with regard to monitoring remission status (Zanatta et al., 2003; Elliott et al., 2011).  
 
 Biomarkers for canine lymphoma  
The human literature on lymphoma related biomarkers is extensive and its potential 
relevance to veterinary medicine has generated wide-spread interest in biomarkers for 
canine LSA. Many markers found in tissue biopsies and blood (whole blood, serum and 
plasma) have been assessed for predictive or prognostic value and used to monitor 
response to treatment or remission status. Blood biomarkers are particularly useful in 
monitoring dogs with internal disease and without peripheral nodal involvement, since 
they avoid the need for repeat imaging/more invasive techniques.  
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 Thymidine Kinase 
Thymidine kinase (TK) is a cytoplasmic enzyme, involved in DNA synthesis. TK 
expression correlates with the fraction of cells in the “S phase” of the cell cycle, and as 
such can be used as an indicator of the proliferative activity of tumour cells (Von Euler 
et al., 2004, 2011; Elliott et al., 2011; Falk, 2018; Boyé et al., 2019). In human literature 
serum TK levels are prognostic and can predict response to treatment in a variety of 
haematological neoplasia, including leukaemia, multiple myeloma, HL and NHL 
(Nakamu et al., 1997; Von Euler et al., 2004, 2008, 2011; Elliott et al., 2011; Boyé et al., 
2019). In dogs, serum TK concentrations were significantly greater in patients with 
neoplasia (Selting et al., 2015, 2016), with concentrations >4.9U/l reported as 73% 
sensitive and 84% specific for a diagnosis of neoplasia (Selting et al., 2015), and both 
serum and plasma TK concentrations particularly elevated in LSA and leukaemia 
(Nakamu et al., 1997; Von Euler et al., 2004, 2011; Selting et al., 2016).  
Serum TK concentrations, as determined by radioenzyme assay and enzyme-linked 
immunosorbent assay (ELISA), were significantly elevated in dogs with LSA, in 
comparison to healthy controls (Von Euler et al., 2004; Boyé et al., 2019), and when 
compared to dogs with inflammatory diseases or non-haematologic tumours (Von Euler 
et al., 2008; Boyé et al., 2019). Although one study (Elliott et al., 2011) found only 47% 
of dogs with LSA had elevations in serum TK at time of diagnosis. 
In some studies (Von Euler et al., 2004, 2008; Boyé et al., 2019) serum TK concentrations 
correlate with WHO disease stage and substage, with higher TK levels associated with 
more advanced clinical stage, and substage b, although results have been conflicting 
(Elliott et al., 2011). Additionally, TK levels are higher in dogs with B-cell LSA, in 
comparison to T-cell LSA (Elliott et al., 2011; Boyé et al., 2019), and are particularly 
elevated in DLBCL in comparison to other subtypes (Boyé et al., 2019).   
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Only one study has found TK levels prognostic for outcome, with a pre-treatment serum 
TK >30U/l associated with significantly shorter survival times (Von Euler et al., 2004). 
Any association with prognosis has been refuted by other studies, finding no link between 
elevations in TK, survival time, duration to first remission, or poorer prognosis (Elliott et 
al., 2011; Falk, 2018). These conflicting results have limited the use of pre-treatment TK 
levels as a prognostic marker. However, serum TK levels have been shown to decrease, 
back to within normal range, in dogs achieving CR (Von Euler et al., 2004, 2008, 2011; 
Boyé et al., 2019), and will rise again, in the weeks prior to clinically detectable relapse 
(Von Euler et al., 2004; Boyé et al., 2019), indicating potential as a predictive biomarker 
or monitoring tool for disease remission.  
 Lactate Dehydrogenase 
Lactate dehydrogenase (LDH) is a ubiquitous enzyme, with five separate isoforms 
identified across virtually all tissues. It is responsible for the conversion of lactate to 
pyruvate during anaerobic glycolysis and is often high in malignant cells, as these use 
anaerobic glycolysis as a primary mechanism of generating energy (Modiano, 2012). 
Serum LDH activity is also a marker of tissue necrosis or damage (Marconato et al., 
2009; Terragni et al., 2016) as malignant or damaged tissues release LDH into the 
circulation (Marconato et al., 2010; Terragni et al., 2016). Elevations in LDH activity 
can be seen in a variety of conditions, including infarction, hepatopathies, myopathies 
and malignancy (Marconato et al., 2009, 2010). LDH has been evaluated in various 
human neoplasms, including carcinomas and haematopoietic neoplasia (Zanatta et al., 
2003; Marconato et al., 2009, 2010; Terragni et al., 2016; Zandvliet, 2016), with serum 
levels showing some correlation to tumour burden (Marconato et al., 2009, 2010). 
Serum LDH levels may also help differentiate between benign and malignant neoplasia 
in the female reproductive tract (Marconato et al., 2009). 
Serum LDH is commonly increased in HL, NHL, multiple myeloma and leukaemia 
(Marconato et al., 2009, 2010; Terragni et al., 2016), and is an important prognostic 
factor in human NHL, with increased LDH activity correlating with reduced survival 
times, disease progression and poor response to treatment (Zanatta et al., 2003; 
Marconato et al., 2010; Terragni et al., 2016; Zandvliet, 2016).  
In veterinary medicine, LDH has been evaluated in healthy dogs, dogs with non-
neoplastic conditions and a variety of different neoplasms (Marconato et al., 2009; 
Terragni et al., 2016), with a reference range for LDH in canine serum and CSF 
 
16 
 
established (Kopanke et al., 2018), facilitating future studies of canine LDH as a 
potentially useful biomarker. 
Dogs with neoplasia had significantly higher mean LDH than healthy dogs, and those 
with non-neoplastic disease, although significant overlap was noted (Marconato et al., 
2009). Increased LDH was however, a poorly sensitive and non-specific marker of 
neoplasia, only elevated in around 45% of neoplasia, with nearly 30% of non-neoplastic 
conditions also having increased and no diagnostic cut out point established (Marconato 
et al., 2009). Elevations in LDH have been specifically reported in both canine 
leukaemia and LSA (Greenlee et al., 1990; Zanatta et al., 2003; Marconato et al., 2009), 
with mean LDH levels in canine LSA significantly higher than those with carcinoma or 
mast cell tumours, and over 78% of canine LSA having elevated LDH at presentation 
(Marconato et al., 2009). 
Correlation between serum LDH at time of  LSA diagnosis and stage of disease has not 
been proven (Von Euler et al., 2006; Marconato et al., 2009), and reports disagree as to 
whether elevated serum LDH levels, in canine LSA, at diagnosis, are prognostic for 
survival, with only one study (Zanatta et al., 2003) suggesting low LDH levels 
correlated with longer survival times. This is in contrast to other findings (Greenlee et 
al., 1990; Von Euler et al., 2006; Marconato et al., 2010). These conflicting reports in 
the literature limit the utility of LDH as a prognostic biomarker. 
While not useful as a diagnostic tool or prognostic biomarker for survival time, canine 
serum LDH activity may have prognostic merit in predicting LSA recurrence following 
treatment. Dogs with elevated serum LDH activity following chemotherapy, were more 
likely to relapse within 45 days (Marconato et al., 2010). Thus, evaluation of LDH 
activity following treatment may predict early relapse, however the usefulness of this 
test is limited by poor sensitivity (Marconato et al., 2010).    
 C - reactive protein 
C-reactive protein (CRP) is an acute phase protein, produced by the liver in response to 
stress, inflammation or infection (Tecles et al., 2005; Nielsen et al., 2007; Nakamura et 
al., 2008; Fontaine, 2013). Widely used as a surrogate marker of disease and disease 
response, in both human and veterinary medicine, CRP concentrations are elevated in a 
variety of inflammatory diseases, and particularly in cases of neoplasia or immune-
mediated disease (Tecles et al., 2005; Merlo et al., 2007; Nielsen et al., 2007; 
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Nakamura et al., 2008; Fontaine, 2013; Kučer et al., 2018). Serum CRP has been used 
as both a diagnostic and prognostic (Merlo et al., 2007; Nielsen et al., 2007; Fontaine, 
2013; Alexandrakis et al., 2017) marker, in human lymphoid neoplasia, with elevated 
CRP at time of diagnosis reflective of both disease burden and poor prognosis 
(Fontaine, 2013).   
Serum CRP has potential as a highly sensitive, although non-specific serum biomarker 
for canine LSA (Merlo et al., 2007; Mischke et al., 2007; Nielsen et al., 2007; Fontaine, 
2013; Fontaine et al., 2017), with CRP levels significantly elevated in dogs with LSA 
prior to treatment, in comparison to a healthy control population (Tecles et al., 2005; 
Merlo et al., 2007; Mischke et al., 2007; Nielsen et al., 2007; Nakamura et al., 2008; 
Fontaine, 2013), and CRP levels above reference range in >85% of canine LSA 
(Fontaine, 2013). Despite high sensitivity, there remains an overlap with normal dogs, 
and many other inflammatory diseases, and serum CRP levels in a number of canine 
LSA patients remains within normal limits (Nielsen et al., 2007; Fontaine, 2013). CRP 
levels may correlate with burden of disease and levels may be higher with HG LSA 
(Mischke et al., 2007; Fontaine, 2013; Bryan, 2016), however no study has found 
individual CRP levels to hold prognostic value (Fontaine, 2013).   
CRP levels reduce following induction of remission with chemotherapy, although may 
remain elevated in comparison to controls, and increase again at time of relapse (Merlo 
et al., 2007; Nielsen et al., 2007; Fontaine, 2013). Elevations in CRP levels do not 
appear to precede relapse (Merlo et al., 2007; Fontaine, 2013; Bryan, 2016; 
Alexandrakis et al., 2017), limiting the use of CRP as a monitoring tool during 
remission.  Additionally CRP levels were not significantly different in CR, in 
comparison to PR or SD (Nielsen et al., 2007; Fontaine, 2013), limiting the use of this 
biomarker to measure disease response to treatment.  
 Combination Biomarkers 
Lack of specificity has limited the use of CRP as a biomarker for canine LSA. As such, 
studies have evaluated the use of multiple biomarkers, in combination with CRP, to 
improve disease specificity.  
Using an algorithm combining serum CRP and haptoglobin levels, the canine 
lymphoma blood test (cLBT, Avacta Animal Health), was developed for diagnosis, 
screening, and remission monitoring (Mirkes et al., 2014). The computer based 
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algorithm assessed CRP and haptoglobin levels, combined with age, sex and lymph 
node status, and was generated using data comparing confirmed LSA cases, healthy 
controls and controls with differing diseases (Mirkes et al., 2014; Alexandrakis et al., 
2017).  
Serum cLBT values at diagnosis were significantly associated with survival times, with 
low cLBT values correlating with improved survival (Bryan, 2016; Alexandrakis et al., 
2017), and elevated cLBT values accurately predicting relapse or progressive disease 
(Alexandrakis et al., 2017). The algorithm claimed to detect relapse of LSA, via 
elevation of cLBT values, up to two months prior to the recurrence of clinical signs 
(Mirkes et al., 2014), with both a high sensitivity (93.5%) and specificity (74.2%) for 
predicting disease (Alexandrakis et al., 2017).  
Despite these positive results in LSA prognostics and remission status monitoring, the 
canine lymphoma blood test was withdrawn from production in 2018.  
Serum CRP has also been evaluated in conjunction with TK. The combination of the 
highly sensitive but non-specific acute phase protein, with the more disease specific 
kinase was used to calculate a value termed the Neoplasia Index (NI) (Selting et al., 
2015, 2016). The NI was significantly higher in neoplasia, particularly LSA, in 
comparison to healthy controls, although overlap existed (Selting et al., 2016), with 
sensitivity and specificity, 82% and 91% respectively, for the detection of neoplasia 
where NI levels ≥5.8 (Selting et al., 2015). Marketed as the “TK Canine Cancer Panel”, 
by the VDI Laboratory in the USA, this combination of biomarkers can aid in the 
diagnosis of neoplasia, particularly LSA, where high values are associated with, 
although not specific for, disease (Selting et al., 2016). While the NI may correlate with 
disease status and remission, any prognostic significance has not yet been proven 
(Bryan, 2016).  
The modified Glasgow Prognostic Score (mGPS) uses a combination of pre-treatment 
serum CRP and albumin levels to generate a numerical score (Kim et al., 2014). In 
human neoplasia, the mGPS has potential prognostic use in DLBCL (Kim et al., 2014).  
Similarly evaluated in canine LSA (Fontaine et al., 2017), the mGPS had prognostic 
potential and was inversely associated with survival time and progression free survival. 
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 Additional acute phase proteins  
Haptoglobin and albumin have both been used, as prognostic and diagnostic biomarkers 
in combination with other factors (Mirkes et al., 2014; Alexandrakis et al., 2017; 
Fontaine et al., 2017). Additionally, they have been each been evaluated as separate 
entities.  
Albumin is a negative acute phase protein, decreasing in response to stress and 
inflammation. Hypoalbuminemia is an independent negative prognostic factor in canine 
LSA and was significantly associated with higher stage and substage b (Fontaine et al., 
2017). Hypoalbuminemia at diagnosis was associated with reduced OST (Romano et 
al., 2016) and PFS (Price et al., 1991; Fontaine et al., 2017).  
Haptoglobin levels are significantly increased in neoplasia, particularly in dogs with 
acute lymphoid leukaemia and LSA, in comparison to healthy controls (Mischke et al., 
2007). A study (Atherton et al., 2013a, 2013b) of the canine serum proteome identified 
haptoglobin in the serum of patients with LSA, and absent in healthy controls, with 
haptoglobin elevations greater with increased burden of disease (Bryan, 2016). While 
there is an inference that increased haptoglobin levels carry an unfavourable prognosis 
(Vail et al., 2019), there are no studies evaluating the independent prognostic 
significance of haptoglobin.  
Serum amyloid A (SAA) is considered a major canine acute phase protein, showing an 
increase in serum concentration in response to a variety of infectious, inflammatory and 
neoplastic diseases (Tecles et al., 2005; Merlo et al., 2008). When evaluated in 
combination, there was good correlation between CRP and SAA concentrations, 
however the high degree of individual variation for SAA concentrations limited utility 
(Tecles et al., 2005). SAA was further evaluated as a biomarker for relapse of canine 
MLSA (Merlo et al., 2008). While mean SAA concentrations were significantly higher 
in dogs with LSA prior to treatment in comparison to controls, there was no increase in 
SAA concentration at time of relapse, rendering SAA redundant as a biomarker for 
monitoring remission or LSA relapse.  
Serum alpha 1-acid glycoprotein (AGP) is an acute-phase protein and serum marker of 
inflammation and neoplasia, with concentrations elevated in neoplasia, in comparison to 
healthy controls, although this was not specific for haematopoietic neoplasia (Ogilvie et 
al., 1993). Serum AGP was also evaluated for use as a marker of LSA relapse (Hahn et 
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al., 1999); AGP concentrations were higher in LSA in comparison to healthy controls, 
and  normalised following doxorubicin treatment. Additionally, mean serum AGP levels 
at the time of relapse, and 3 weeks prior to relapse were significantly higher than that 
measured while in remission, and not significantly different to pre-treatment 
concentrations (Hahn et al., 1999). Thus, serum AGP levels could be a useful biomarker 
for predicting LSA relapse prior to clinically detectable disease, although this method is 
not been widely adopted in clinical practice.  
 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a cytokine, with an important role in 
angiogenesis, lymphangiogenesis and metastasis (Dvorak, 2002; Gentilini et al., 2005; 
Aresu et al., 2012). Found to be a useful biomarker in human LSA (Gentilini et al., 
2005), studies have shown that serum and plasma VEGF are also elevated in canine 
LSA in comparison to healthy controls (Gentilini et al., 2005; Aresu et al., 2012). 
VEGF concentrations appear to correlate with other poor prognostic indicators, with 
VEGF higher in HG LSA, substage b, stage V and T-cell LSA (Gentilini et al., 2005; 
Aresu et al., 2012).   
Serum VEGF concentrations have some prognostic significance, with one study 
(Gentilini et al., 2005) finding high levels correlate negatively with DFI. Although 
VEGF levels did not correlate with likelihood of achieving remission or overall survival 
(Gentilini et al., 2005; Aresu et al., 2012), plasma VEGF concentrations did decrease in 
B-cell LSA following treatment, suggesting a possible predictive role in these cases.  
 Matrix metalloproteinases  
Matrix metalloproteinases (MMP) are enzymes, important in the breakdown of 
extracellular matrix (ECM) proteins. Through the breakdown of cell-cell and cell-ECM 
adhesions, MMPs are integral to cell migration and differentiation, metastasis and 
angiogenesis (Shao et al., 2013). MMP 2 and 9 are useful biomarkers in human LSA, 
associated with invasion, metastasis, cell migration and angiogenesis (Aresu et al., 
2012; Huang et al., 2015). MMP’s have a role in LSA pathogenesis and high levels are 
associated with an unfavourable prognosis in human NHL (Aricò et al., 2013). 
Subsequent studies have shown that plasma and serum MMP 9 are significantly higher 
in dogs with LSA, in comparison to healthy controls (Gentilini et al., 2005; Aresu et al., 
2012; Huang et al., 2015).  
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Both MMP 2 and 9 were significantly higher in dogs with WHO substage b compared 
to substage a (Gentilini et al., 2005), and higher in T-cell LSA in comparison to B-cell 
LSA (Aresu et al., 2012; Huang et al., 2015). Additionally MMP 9 was higher in stage 
V disease, in comparison to stage III-IV (Aresu et al., 2012). While no prognostic 
significance could be attributed to pre-treatment levels of serum or plasma MMPs 
(Gentilini et al., 2005; Aresu et al., 2012; Huang et al., 2015), MMP 9 decreased 
following treatment (Aresu et al., 2012; Huang et al., 2015), suggestive of a potential 
benefit as a predictive marker. 
 Serum biochemistry parameters  
In addition to specific biomarkers, as biochemistry is frequently assessed as part of 
routine staging, there has been interest in the potential prognostic value of various 
biochemical parameters.  
Alkaline phosphatase (ALKP) is a membrane-bound glycoprotein, responsible for the 
hydrolysis of phosphate esters (Johnston, 2017). Abnormalities in serum ALKP are 
common biochemical findings (Comazzi et al., 2004), with canine serum ALKP 
increasing in response to necrosis, inflammation, neoplasia and hepatobiliary disease 
(Johnston, 2017). ALKP has been evaluated with regard to prognosis in canine LSA, 
but was not a significant indicator of response or progression free survival (Wiedemann 
et al., 2005).  
Cobalamin (vitamin B12) is required for the synthesis of nucleic acids, essential 
haematopoiesis and a cofactor for multiple enzyme systems. Dogs are unable to 
synthesize cobalamin and thus reliant on dietary absorption. Hypocobalaminaemia is 
associated with small intestinal disease and is an independent poor prognostic factor for 
chronic canine enteropathies (Allenspach et al., 2007). Hypocobalaminaemia has also 
been recorded, although not evaluated for significance, in LG gastrointestinal LSA 
(Lane et al., 2018). While relatively uncommon in canine MLSA, hypocobalaminaemia 
was associated with a poor outcome and shorter OST (Cook et al., 2009), suggesting 
that serum cobalamin concentrations may be prognostic.  
Hypercalcaemia of malignancy is a common paraneoplastic syndrome, frequently 
associated with T-cell LSA (Zandvliet, 2016; Bailey, 2019), with hypercalcaemia at 
diagnosis independently associated with a poor prognosis (Marconato et al., 2011; 
Burton et al., 2013; Zandvliet, 2016; Vail et al., 2019). Calcium levels can be used as a 
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biomarker to monitor response to therapy in LSA and other neoplasia, with recurrence 
of hypercalcaemia, following successful treatment, frequently a marker of relapse (Vail 
et al., 2019).   
 Haematology parameters  
Similarly, studies have evaluated the use of routine haematological parameters as 
prognostic or predictive biomarkers.   
Anaemia, usually consistent with an anaemia of chronic disease, is one of the most 
common haematological abnormalities found in canine LSA (Vail et al., 2019). 
Anaemia at presentation is a negative prognostic indicator (Davies et al., 2018; Vail et 
al., 2019) associated with shorter OST (Abbo et al., 2007; Miller et al., 2009; Romano 
et al., 2016) and  PFS (Childress et al., 2018; Davies et al., 2018). Anaemia at time of 
diagnosis was also associated with an increased risk of incomplete remission (Childress 
et al., 2018). 
Thrombocytopenia is thought to occur in 30-50% of canine LSA diagnosis (Grindem et 
al., 1994; Zemann et al., 1998; Vail et al., 2019). Although rarely causing clinically 
significant haemorrhage or petechiation, thrombocytopenia is associated with 
incomplete remission (Childress et al., 2018), decreased progression free interval 
(Zemann et al., 1998; Moore et al., 2001; Burton et al., 2013; Childress et al., 2018), 
decreased survival times (Burton et al., 2013), and generally a poor overall outcome 
(Childress et al., 2018; Vail et al., 2019) in canine LSA patients. A small number of 
studies have, however, associated thrombocytopenia with increased survival times 
(Garrett et al., 2002; Rebhun et al., 2011), and made a tentative link between 
thrombocytopenia and T-cell immunophenotype (Rebhun et al., 2011).  
Individual blood leucocyte counts have also been evaluated, with neutrophilia 
associated with poor response rates (Purzycka et al., 2020), reduced PFS (Childress et 
al., 2018) and described as an unfavourable prognostic factor (Childress et al., 2018; 
Vail et al., 2019). Monocyte and neutrophil numbers were both found to be significantly 
elevated in dogs with LSA (Perry et al., 2010), in comparison to healthy controls, and 
elevated neutrophil and monocyte counts were both found to be predictive of reduced 
DFI (Perry et al., 2010), even when values remained within reference ranges.  
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Ratios of leucocytes have also been evaluated for prognostic significance. The 
neutrophil:lymphocyte ratio (NLR) compares the inflammatory response to the host 
immune response (Mutz et al., 2013). Studies have identified a potential prognostic 
significance, for both PFS and OST, although a consensus is lacking (Mutz et al., 2013; 
Davies et al., 2018). Similarly, the value of the lymphocyte:monocyte ratio (LMR) has 
also been assessed, with low LMR levels predictive of shorter time to disease 
progression, and OST (Marconato et al., 2015b) and LMR > 1.43 predictive of longer 
overall survival (Davies et al., 2018). The LMR was also significantly associated with 
incomplete remission (Childress et al., 2018).  
 
 Summary 
While multiple biomarkers have been assessed, there is no individual marker, or 
combination of markers which have become mainstream biomarkers used in clinical 
practice. Limitations regarding the sensitivity and specificity of individual markers for 
diagnosis, disparity between studies and individual variation has hindered the use of 
single biomarkers for diagnostic, prognostic or predictive purposes.  
 
 Clusterin 
Clusterin (CLU), is a glycoprotein, also known as apolipoprotein J (APO-J). CLU was 
initially identified in the fluid of ram rete testes, and can be seen to elicit aggregation, or 
clustering, of a variety of different cells (Fritz et al., 1983). The CLU protein can be 
identified in virtually all tissues and body fluids (Flach et al., 1995; Bettuzzi, 2009; Rizzi 
et al., 2009b), and is well conserved across species (Michel et al., 1997; Calero et al., 
1999; Wilson et al., 2000). Investigated and described under multiple names, across 
numerous different species, many species specific homologues of the CLU protein have 
been identified (Jenne et al., 1992; Rosenberg et al., 1995; Jones et al., 2002) (Table 1). 
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Table 1)  
Synonyms/homologues of the CLU protein 
 
Name Source: 
species/tissue 
Identification/function Reference 
Apolipoprotein J 
(Apo-J) 
Human, 
serum 
High density 
lipoprotein/apolipoprotein, 
involved in lipid transport 
(de Silva et al., 
1990; De Silva et 
al., 1990) 
Complement 
cytolysis inhibitor 
(CLI) 
Human, 
serum (liver) 
Part of the complement 
complex, complement 
modulator 
Also identified in semen. 
(Jenne et al., 1989) 
pADHC-9 Human, brain Found in the hippocampus of 
an Alzheimer’s patient 
(May et al., 1989, 
1990) 
pTB-16 Human, brain Found in glioma and expressed 
in epileptic foci 
(Danik et al., 1991) 
Serum protein-
40,40 
(SP-40,40) 
Human, 
serum 
Complement modulator, 
component in immune deposits 
in glomerular disease. 
(Murphy et al., 
1988; Kirszbaum et 
al., 1989) 
Glycoprotein 80  
(Gp-80) 
Dog, renal Glycoprotein secreted from the 
apical surface of renal 
epithelial cells 
(Urban et al., 1987; 
Hartmann et al., 
1991) 
Glycoprotein III  
(Gp-III) 
Cow, adrenal Component of chromaffin 
secretory granules 
(Fischer‐Colbrie et 
al., 1984; Palmer et 
al., 1990) 
Clusterin 
(CLU) 
Sheep, Ram 
rete teste 
fluid 
Protein from testis fluid, 
functions in reproduction, 
elicits cell aggregation activity 
(Blaschuk et al., 
1983; Fritz et al., 
1983) 
Sulfated 
glycoprotein-2 
(SGP-2) 
Rat, Sertoli 
cell 
Sertoli cell secretion product, 
found on sperm membranes, 
functions in reproduction 
(Collard et al., 
1987; Bettuzzi et 
al., 1989; Sylvester 
et al., 1991) 
Testosterone 
repressed prostatic 
messenger-2  
(TRPM-2) 
Rat, prostate Found during involution of 
prostate following androgen 
withdrawal, involved in 
apoptosis 
(Leger et al., 1987; 
Buttyan et al., 
1989) 
 
Synonyms/homologues of the CLU protein found in a variety of different tissues, across different species 
(Jenne et al., 1992; Fritz et al., 1993; Bettuzzi, 2009).   
 
25 
 
Human CLU was first described in 1989 (Jenne et al., 1992) as a complement cytolysis 
inhibitor (CLI) found in serum, with other synonyms including APO-J, sulfated 
glycoprotein-2 (SGP-2), serum protein-40,40 (SP-40,40), testosterone repressed prostatic 
messenger 2 (TRPM-2), and glycoprotein 80 (Gp-80) (Jenne et al., 1992; Bettuzzi, 2009; 
Foster et al., 2019), all of which have been identified as proteins produced from the same 
gene. A single-copy gene, the human CLU gene comprises 9 exons and is  located  on  
chromosome  8 (Figure 1), with the canine CLU gene, identified on chromosome 25 
(Slawin et al., 1990; Tobe et al., 1991; Jones et al., 2002; Foster et al., 2019; NCBI, 
2019).  
 
 
 
Figure 1: 
 
CLU gene structure.  
Secretory CLU is derived from mRNA transcript NM_001831.3, with translation 
beginning in exon two, producing the immature CLU precursor  
 
(Adapted from Foster, 2019).  
 
Gene expression is tightly controlled (Foster et al., 2019), however upregulation of CLU 
mRNA and protein are widespread phenomena in developmental and pathophysiological 
states, suggesting that control of expression levels is dynamic (Jones et al., 2002). 
Numerous factors have been suggested as regulatory for CLU gene expression, including 
nuclear factor-κβ, growth factors, stress and ionising radiation, with cell death and 
apoptotic signalling also thought to play key roles (Trougakos et al., 2009b; Foster et al., 
2019).  
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 Clusterin structure/form  
Although a single gene, the CLU gene codes for different protein products; nuclear, 
cytoplasmic and secretory, each with different biological functions (Rizzi et al., 2009b, 
2010). Thus CLU could be thought of as a group of protein products as opposed to one 
single protein (Bettuzzi, 2009).  
The structure of the CLU protein shows little variation between species (Michel et al., 
1997; Calero et al., 1999; Wilson et al., 2000). In humans, the mature form of secretory 
CLU is a heterodimeric glycoprotein of 75–80kDa (Jenne et al., 1992; Bettuzzi, 2009; 
Naponelli et al., 2017), which tends to dissociate into non identical subunits, the alpha 
and beta chains, each of approximately 40kDa (Figure 2) (Jenne et al., 1992; Bettuzzi, 
2009). The structure of the protein itself, with coiled/helical domains, allows CLU to 
interact in a stable manner, with both lipids and other proteins (Michel et al., 1997). The 
ability of CLU to bind to a variety of different ligands facilitates the protein’s diverse 
biological function (Calero et al., 1999). 
 
 
Figure 2: 
 
CLU protein structure.  
The immature CLU precursor protein is present as a non-glycosylated protein, of around 
60-64kDa, which undergoes processing in the endoplasmic reticulum and maturation 
within the Golgi apparatus.  
 
The protein is cleaved and modified, by glycosylation and phosphorylation, to produce 
the mature secretory CLU which comprises of two protein monomers, termed α and β, 
which are linked via five disulphide bonds. The resultant protein is a highly glycosylated 
heterodimer, of 75-80kDa, comprised of two approx. 40kDa subunits/chains.  
 
(Urban, 1987; Federica Rizzi, 2009; Figure adapted from Foster, 2019).  
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Secretory CLU, formed in the Golgi apparatus, is exported from the cell and enters the 
extracellular compartment as a glycosylated protein (Bettuzzi, 2009). Intracellular CLU 
can be cytoplasmic and/or nuclear, with CLU staining commonly detected concurrently, 
in intact, fixed cells (Bettuzzi, 2009). 
 
 Clusterin function 
Often termed an enigmatic and ubiquitous protein, the biological and pathogenic 
functions of CLU have been poorly defined (Bettuzzi, 2009). CLU has been implicated 
in many different roles, including cell-cell interaction, transportation and regulation 
(Wilson et al., 2000). However, the exact nature and function of the protein in vivo are 
elusive.  
From the extracellular compartment CLU binds to a number of serum proteins including 
albumin (Wyatt et al., 2010) and complement factors. CLU is heavily glycosylated, a 
feature which can affect both the nature of the protein itself, and its binding properties. 
Widely expressed throughout the body (Flach et al., 1995; Jones et al., 2002; Trougakos 
et al., 2002, 2004; Bettuzzi, 2009), CLU acts as an extracellular chaperone protein 
(Wilson et al., 2000), acting to stabilise protein folding. CLU will aid in correction or 
facilitate degradation of misfolded proteins and assist in the clearance of proteins from 
extracellular spaces (Humphreys et al., 1999; Wilson et al., 2000, 2017; Trougakos et al., 
2009a; Wyatt et al., 2009, 2010). Functioning similar to the small heat-shock proteins 
(Humphreys et al., 1999; Wyatt et al., 2009; Wilson et al., 2017), an increase in CLU 
expression, regulated by cytokines and growth factors, has been shown to correlate with 
physiological stress (Michel et al., 1997; Humphreys et al., 1999; Trougakos et al., 2002, 
2004; Shannan et al., 2006; Wyatt et al., 2009; Wilson et al., 2017). The chaperone 
function of secretory CLU is widely described; protecting cells from physical stress and 
neutralizing cellular insult, CLU also facilitates clearance and disposal of toxic molecules 
from within the cell (Wilson et al., 2000, 2017). CLU has been linked to multiple 
biological processes; including apoptosis, tissue remodelling, membrane recycling, cell 
cycle regulation and immune system regulation (Wilson et al., 2000; Jones et al., 2002; 
Trougakos et al., 2002; Pucci et al., 2004; Shannan et al., 2006). 
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In addition to a physiological role, CLU has also been implicated in a number of 
pathological processes including tumorigenesis and regulation of cell death (Trougakos 
et al., 2002; Shannan et al., 2006; Wilson et al., 2017). As may be expected, given the 
role of CLU and cell cycle regulation and death, CLU has also been implicated in the 
aging process. In humans, a relationship has been evaluated between CLU expression and 
age, with CLU expression increasing from gestation to adulthood (Mondello et al., 1999; 
Trougakos et al., 2002, 2006), although significant individual variation exists. 
 Clusterin in neoplasia  
Dysregulation of CLU has been associated with various human malignancies (Saffer et 
al., 2002; Shannan et al., 2006; Rizzi et al., 2010; Frazzi et al., 2011). Multiple studies 
identified positive IHC staining for cytoplasmic and nuclear CLU, as well as increases in 
serum CLU (Rodriguez-Pineiro et al., 2006; Nafee et al., 2012; Guo et al., 2014), in a 
variety of epithelial neoplasia (Steinberg et al., 1997; Redondo et al., 2000; Kang et al., 
2004; Pucci et al., 2004; Yom et al., 2009),  including prostatic (Steinberg et al., 1997; 
Rizzi et al., 2010) and mammary carcinoma (Redondo et al., 2000; Krüger et al., 2007; 
Yom et al., 2009; Rizzi et al., 2010), oesophageal squamous cell carcinoma (Guo et al., 
2014), hepatocellular carcinoma (Nafee et al., 2012) and colorectal neoplasia (Pucci et 
al., 2004; Rodriguez-Pineiro et al., 2006). CLU has been implicated both as a tumour 
suppressor (Bettuzzi et al., 2009; Trougakos et al., 2009a) and  a modifier of tumour 
promotion (Trougakos et al., 2009a). Some human studies have suggested that down 
regulation, and subsequent loss of the CLU chaperone function, could play a role in the 
development of neoplasia (Scaltriti et al., 2004; Shannan et al., 2006; Rizzi et al., 2008, 
2010), with others suggesting that dysregulation of CLU expression, both upregulation or 
downregulation, can have an impact on tumorigenesis. 
 Clusterin in human lymphoid neoplasia 
Cytoplasmic expression of CLU has been positively identified, via IHC, in cases of 
anaplastic large cell LSA (Wellmann et al., 2000; Lae et al., 2002; Saffer et al., 2002; 
Nascimento et al., 2004). Positive staining is less common in other forms of T-cell and 
B-cell LSA (Wellmann et al., 2000; Saffer et al., 2002; Nascimento et al., 2004), with 
Saffer et al. (2002) identifying cytoplasmic CLU staining in 35% of lymphoid neoplasia 
assessed; and present in only a small subset (12%) of DLBCL cases.  
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CLU has also been identified in vitro (Coletta et al., 2012), in the Toledo DLBCL cell 
line. Very low levels of CLU were identified, via fluorescence microscopy and real-time 
PCR, in the LSA cell line in comparison to B lymphocytes from healthy human blood. 
With regard to lab based cell lines, it has been shown that doxorubicin treatment 
upregulates secretory CLU isoforms (Frazzi et al., 2011; Coletta et al., 2012), this has 
also been shown in vivo, with serum CLU expression upregulated in a subset of patients 
following treatment for HL (Frazzi et al., 2011).  
 
 Canine clusterin 
Canine CLU has been evaluated as a marker in various inflammatory and disease states. 
Studies evaluating serum and plasma of overweight dogs identified CLU overexpression, 
with levels decreasing in line with weight loss (Tvarijonaviciute et al., 2012, 2013). 
Urinary (García-Martínez et al., 2012; Zhou et al., 2014)  and renal tissue CLU (Tsuchiya 
et al., 2005) were increased in response to renal damage, with urinary CLU levels 
significantly increased following intravenous (IV) contrast agent administration (Fowlie 
et al., 2017). Additionally, evaluation of CSF found CLU levels to be higher in canine 
degenerative myelopathy and intervertebral disc disease, in comparison to other 
neurological diseases (Shafie et al., 2014). These changes indicate potential for urinary 
and CSF CLU as early biomarkers for renal or spinal cord disease. Thus far little has been 
reported regarding CLU expression in canine malignancies. 
 Canine clusterin in lymphoma 
In 2013, Atherton et al. characterised the serum proteome of dogs with LSA, via serum 
protein electrophoresis and mass spectrometry. In this study multiple canine proteins, 
which were not previously identified in healthy dogs, were identified in dogs with LSA. 
One of these proteins was a CLU precursor, present in the alpha-2 band of the serum 
proteome of a dog with high grade MLSA and absent in serum from two healthy controls 
(Atherton et al., 2013a). This led to speculation that CLU may have an anti-apoptotic, 
pro-neoplastic role in canine LSA (Atherton et al., 2013a). The CLU protein was also 
identified in a separate study (Fonghem et al., 2017), investigating the proteomic profiles 
of canine LSA, although it was not identified as significantly elevated or decreased in 
LSA in comparison to a small control population.  
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  Aims  
The objectives of this study were to determine if: 
i) serum CLU expression differed significantly between those dogs with high 
grade MLSA, and a healthy control population and therefore had potential as 
a useful diagnostic tool.  
ii) serum CLU expression differed significantly in individual patients following 
successful treatment and induction of remission and therefore had potential 
as a monitoring tool, as a marker of remission, early relapse or treatment 
failure.  
It was hypothesised that serum CLU levels would be higher in those patients with MLSA 
in comparison to healthy controls and may return to “normal” levels following successful 
treatment.  
 
 Subsequent aims  
 Prognostic 
A subsequent aim was to determine whether disease stage, substage or immunophenotype 
was linked to alterations in CLU expression, and subsequently whether CLU expression 
could be linked to prognosis, particularly time to relapse or treatment failure. 
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2 Materials & Methods 
 Sample Selection 
Archived serum samples were selected from canine patients who presented to the Small 
Animal Hospital between 2013 and 2018, with a confirmed cytological or 
histopathological diagnosis of high grade MLSA. Samples from dogs with higher stages 
of disease, as determined by WHO classifications (Owen, 1980), were preferentially 
included. Retrospective analysis of medical records was performed to obtain information 
pertaining to signalment, WHO stage (I-V) and substage (a = no clinical signs, b = clinical 
signs) (Owen, 1980; Vail et al., 2013), confirmation of diagnosis and treatment. 
Exclusion criteria included severely haemolysed or lipemic samples, concurrent 
infectious or systemic inflammatory disease, prior treatment and failure to achieve CR.  
As the study was retrospective, detailed analysis of the medical records was performed to 
obtain case information, particularly WHO stage and substage. Investigations for staging 
were not standardised, and differed between patients, based on historical clinician 
preference. Investigations included complete blood count, serum biochemistry, 
urinalysis, cytology of lymph node, liver, spleen and bone marrow, thoracic imaging, 
either radiographs or computed tomography, and abdominal ultrasound scan. However 
not all investigations were performed for each case. Information regarding 
immunophenotype/genotype and clonality was included where performed, either 
following IHC, flow cytometry, PARR analysis or a combination of these techniques. 
Due to the retrospective nature of the study, and the lack of standardized staging 
investigations, stage migration could not be excluded.  
The study was performed with full ethical approval from the Ethics and Welfare 
committee (Ref 56a/15) at the University of Glasgow, with owner consent (Appendix 1) 
obtained for the retention of spare serum. All serum samples were surplus blood, from 
samples collected for diagnostic and treatment purposes. Clotted serum samples were 
centrifuged at 9000rpm for three min, prior to serum extraction and freezing. All serum 
samples were stored frozen, at -20 °C, prior to transfer for storage at -80 °C, for future 
analysis. 
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 Sample categories   
Samples were grouped into three broad categories: -  
1. Pre-treatment: Samples from dogs with MLSA taken at the time of diagnosis, 
prior to any corticosteroid or chemotherapy treatment 
2. Complete remission (CR): Samples from dogs with MLSA in CR, as determined 
by physical examination and lymph node palpation, at week 4-6 of a (CHOP-
based) chemotherapy protocol (Appendix 2), by a qualified veterinary surgeon 
experienced in veterinary oncology. 
3. Control samples: Serum samples from healthy dogs were obtained from the Pet 
Blood Bank UK. These serum samples were acquired from the dogs for screening 
and monitoring purposes at the time of blood donation. Control samples were 
stored at -20 °C prior to transport and subsequently transported frozen to Glasgow. 
Samples were then stored in the same conditions as the MLSA samples, at -80 °C, 
for future analysis. 
Full sample lists are documented in Appendix 3. 
 
 Sample groups  
All samples were selected, from the previously identified pool of suitable samples and 
controls, to generate distinct sample groups.  
A pilot group of samples, consisting of dogs with MLSA, pre-treatment (n=20) and 
healthy control dogs (n=20) (Table 2), was initially used for optimisation and refinement 
of technique. Latterly, samples were divided into three samples groups for analysis and 
comparison of CLU levels, a small number of samples matched criteria, and were 
included in, multiple sample groups (as outlined in Appendix 3). When creating these 
sample groups, preference was given to samples with shorter storage history, samples 
with larger sample volume, and samples with higher burden of disease (i.e. Stage III or 
above, as per the WHO staging system).  
Sample group one consisted of 3 cohorts; dogs diagnosed with MLSA, pre-treatment (A, 
n=12), unrelated dogs with MLSA, in CR (B, n=12) and healthy control dogs (C, n=12), 
(Table 4). 
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Sample group two consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment 
(n=18), and in CR (n=18), i.e. paired samples from the same individuals, (Table 5). 
Sample group three consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment 
(n=18) and healthy control dogs (n=18). Samples for group three were intentionally 
selected to form age matched cohorts, (Table 6). 
 
 Sample storage and dilution 
Selected samples were thawed in an ice bath. An aliquot of serum (100μl) was removed 
from the sample, labelled and stored as neat serum. A dilution was performed for portion 
of each serum sample, with 10μl of sample diluted; 1:20 in purified water (Milli-QTM) 
and diluted samples divided into aliquots. Aliquots were stored at -20 °C and individual 
aliquots thawed as required. This was in order to reduce the number of freeze/thaw cycles 
for each individual sample. The impact of repeated freeze/thaw cycles on the protein 
content of canine serum, and the stability of the CLU protein in canine serum is as yet 
unknown.   
 
 Protein Quantification  
Total protein concentrations of the canine serum samples were determined using the 
bicinchoninic acid (BCA) protein assay system (Thermo Life Science Ltd, UK). 
 
 Optimisation  
Initial protein assays were performed on 96 well plates, with protein standards and four 
serum samples. Protein standards (BSA 2mg/ml stocks from Thermo LifeScience.uk) of 
varying concentrations (0.05 – 0.8μg/ml) were run, in duplicate, to provide reference 
points and allow generation of a standard curve. The standard curve then facilitated the 
quantification of protein concentration within the samples.  
Serum samples (diluted 1:20) were loaded onto the 96 well plates at volumes of 2.5μl, 
5μl, 75μl, 10μl, 15μl, and 20μl. All samples were run in duplicate and the varying volumes 
used in order to determine optimal sample volume for the protein assay.  
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Initial assays for optimization of sample volume established that the volume of 2.5μl of 
sample/well was optimal for determination of protein concentration.  
 
 Protein Assays 
Diluted samples were thawed, and reagents brought to room temperature. Samples (2.5μl) 
and standards (25μl) were added to the appropriate wells on the microplate, along with 
200μl of buffer solution. Buffer solution was created by mixing Pierce BCA protein assay 
sample Reagent A (10ml) with Reagent B (200μl) prior to adding to each well. The 
microplate was agitated at 350rpm on an orbital microplate shake for 30s and incubated 
for 30 min at 37.0°C. After incubation, the plate was read immediately at 562nm on a 
microplate reader, using Ascent software (Multiskan Ascent, MTX Lab Systems). Data 
was analysed using Microsoft Excel, (2010) and GraphPad Prism software, version 5 for 
Windows (GraphPad Software, San Diego, California, USA), with a calibration curve 
generated using protein standards to determine the protein concentrations of each sample.   
 
 Assessment of serum clusterin levels 
Serum CLU levels in individual samples were assessed using two separate techniques:- 
western blot was performed, to confirm the detected protein had the predicted molecular 
weight, using a previously validated (Shafie et al., 2013, 2014) commercial anti-human 
antibody, predicted to have cross species reactivity with dog (at 93%). Initial experiments 
were performed to confirm the specificity of the antibody (a comparison of a western blot 
with the CLU primary antibody and secondary antibody only) and sensitivity of the 
method (signal intensity of CLU versus increased amount of protein loaded onto the gel). 
An ELISA was also performed using a commercial (BioVendor Ltd) kit, to increase the 
throughput of samples in larger quantities. The assay was previously validated, by 
BioVendor, using canine serum, and validation was not specifically repeated during these 
investigations. 
 
 Western Blot  
Western blot analysis was performed as previously described (Shafie et al., 2013, 2014). 
Initially, protein concentrations of the serum samples were determined using the BCA 
protein assay system (Thermo Life Science Ltd, UK) as described in section 2.3.  
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 Gel electrophoresis  
Serum sample aliquots (10μg protein, as determined by optimisation experiments, 
described in section 3.1) were diluted with purified water (Milli-QTM) to give a sample 
volume of 10μl. Five microliters of 3x denaturing buffer (BioRad Ltd, UK) containing 
freshly added dithiothreitol (DTT) to give a final concentration of 50mM was added to 
each of the sample tubes, to facilitate denaturation of the proteins, prevent disulphide 
bond reformation and attach negatively charged sodium dodecyl sulfate (SDS) and allow 
electrophoretic separation of the proteins. Samples were centrifuged for six seconds at 
9000rpm, incubated at 90°C for four min, then loaded on to the gel. 
Samples were then separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS – PAGE) using Criterion 18 or 26 well gels (BioRad Ltd, UK). 
Samples from diseased and control dogs were loaded in alternate wells, with protein 
molecular weight standards (BioRad Ltd, UK) run in the first and last well of each gel. 
Electrophoresis was performed in 5% MES (2(N-morpholino) ethanesulfonic acid) 
buffer, with a voltage ranging between 130-145 V, for 45-60 min.  
Following electrophoresis samples were transferred to nitrocellulose membranes using 
the iBlotTM system (Invitrogen, Thermo Fisher, UK). Initial gels were run and stained 
with Coomassie Brilliant Blue (Figure 3), to allow visualisation of remaining individual 
protein bands and confirm equal loading across the sample lanes. When outliers were 
apparent, the protein assay and SDS-PAGE process was repeated. 
 
 
 
Figure 3:  
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Gel electrophoresis of serum samples showing separation of protein by molecular 
weight. 
 
 Antibody incubation 
Following transfer, the membranes were blocked in 5% semi skimmed milk solution, with 
Tris-buffered saline (pH 7.4) containing 0.5% Tween 20 (T-TBS), at room temperature, 
at 300rpm on an orbital microplate shaker. Blots were washed, three times with 0.5% T-
TBS solution and incubated overnight at 4°C, with a goat primary antibody against anti-
human CLU (Antibody 104652, Abcam Ltd, UK), diluted 1:20,000, with gentle shaking 
at 300rpm on an orbital microplate shaker.  
Two separate commercial, primary antibodies were initially analysed to assess which 
generated the cleanest signal with minimal nonspecific background, with the canine 
samples. The primary antibodies, raised in goat against a human CLU protein, were 
compared; Abcam anti-clusterin antibody 39991 (991) and anti-clusterin antibody 
104652 (652), (Figure 4A). More consistent staining, at the correct molecular weight 
(37kDa), was seen with antibody 652 and all further western blots were performed with 
this antibody. 
To determine optimal primary antibody concentration, dilutions of the primary antibody 
were made in 5% semi skimmed milk solution with (T-TBS) to 1:10,000, 1:20,000 and 
1:50,000. Protein band density and background interference were analysed on 
radiographic films after performing electrophoresis. Whilst a 1:10,000 dilution was 
initially used for the pilot samples, comparison of dilutions showed that a 1:20,000 
dilution of the primary Abcam anti-clusterin antibody 104652 provided the best signal, 
with minimal background interference and was therefore used for ongoing analysis.  
After incubation with the primary antibody, the blots were washed with 0.5% T-TBS 
solution, repeated three times. Membranes were then incubated with a horseradish 
peroxidase (HRP)-conjugated secondary antibody (Abcam Ltd, UK), diluted to 1:10,000, 
at room temperature. After incubation the blots were washed with 0.5% T-TBS solution, 
repeated three times.  
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 Enhanced Chemiluminescence and film development  
Immunocomplexes were detected using the enhanced chemiluminescence (ECL) reagent 
(Pierce ECL, Thermo Fisher, UK) and the protein bands visualised via radiographic film. 
Equal volumes of ECL reagents were constituted as per manufacturer guidelines. 
Nitrocellulose membranes (blot) were immersed in ECL solution and the solution 
agitated. Excess ECL reagent was removed by gentle blotting with 3MM paper, the blot 
was then enclosed in Saran wrap and images acquired using radiography film and 
standard darkroom development techniques for chemiluminescence. Exposures of 
between 30s to 2 min were found to produce optimal signal intensity for CLU.  The 
radiographic films were then scanned and stored digitally as TIFF files.  
To determine optimal exposure times for radiographic films, different exposure times 
were selected and trialled. Films were exposed to the blot, following ECL contact, for 
30s, 1 minute, 3 minutes and 5 minutes. Protein band density and background interference 
were compared on radiographic films to determine the optimal exposure times. Initial 
pilot studies were performed with exposure times of 5 minutes to generate radiographic 
images. However, elimination of background interference and clarity of CLU bands was 
deemed best at 30s exposures although a range of exposure times were collected due to 
the subtle variations that are encountered with this method. 
 Data analysis  
Data pertaining to protein band density was quantified using Image-J software (Schneider 
et al., 2012), generating numerical values equivalent to the protein signal intensity of each 
sample.  
 
 ELISA  
CLU concentrations were measured using a sandwich enzyme immunoassay (BioVendor 
Ltd, UK) for quantitative measurement of canine CLU.  This assay was previously 
validated, by BioVendor, to have low within‐run imprecision and an intra‐assay 
coefficient of variance (n = 8) of 4.3%, and an acceptable between‐run comparability, 
with inter‐assay coefficients of variance (n = 8) of 6.2%. A normal canine serum CLU 
concentration range has not yet been established.   
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The samples were thawed, and reagents brought to room temperature. Standards, buffers 
and washes were constituted as per manufacturer guidelines (Appendix 4). Samples were 
diluted 1:2500 dilution buffer [to facilitate the ELISA]. The ELISA was run as per 
manufacturer guidelines, using dilution and wash solutions provided.  
Quality control reference samples and CLU standards supplied with the ELISA kit were 
included with each run, along with the diluted samples (100μl) and added to the 
appropriate wells. The plate was incubated for 1h at room temperature with gentle 
shaking, at 300rpm on an orbital microplate shaker. After incubation the plate was washed 
with 350μl of wash solution per well, repeated three times.  
After the final wash, the plate was inverted and blotted with paper towel. Biotin labelled 
antibody (100μl) was added to each well and the plate incubated for one hour at room 
temperature, with gentle shaking. After incubation the plate was washed with 350μl of 
wash solution, repeated three times; the plate was then inverted and blotted.  
Streptavidin-HRP conjugate (100μl) was then added to each well and the plate was 
incubated for 30min at room temperature with gentle shaking. After incubation the plate 
was washed with 350μl of wash solution, repeated three times; the plate was then inverted 
and blotted.  
Tetramethylbenzidine (TMB) Substrate Solution (100μl) was then added to each well and 
the plate incubated for 10min, at room temperature. Finally, 100μl hydrogen peroxide 
stop solution was added to the wells. The plate was read immediately at 450nm and 
650nm on a microplate reader, using Ascent software (Multiskan Ascent, MTX Lab 
Systems). 
 Data analysis  
Data was analysed with Microsoft Excel, (2010) and GraphPad Prism software, version 
5 for Windows (GraphPad Software, San Diego, California, USA). A standard curve was 
generated, using results from the supplied CLU standards, to allow numerical absolute 
values to be generated for the CLU concentrations in each sample.  
 
 
39 
 
 Statistical analysis  
Analyses were performed using GraphPad Prism, version 5 for Windows (GraphPad 
Software, San Diego, California, USA) and Minitab 19 (Minitab® Statistical Software) 
with statistical significance set at P ≤ 0.05. The serum CLU concentrations were analysed 
using parametric and non-parametric testing, depending on normality of data distribution, 
with student t- test, Mann–Whitney U test, analysis of variance (ANOVA) and Wilcoxon 
signed rank tests. Group characteristics were compared using Mann–Whitney U test, 
ANOVA, Chi squared and Fisher’s exact tests.  
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3 Results 
 Optimisation of western blot technique  
Initial optimisation of technique was performed using two canine serum samples, one 
control sample and one MLSA pre-treatment sample. Gel electrophoresis was performed, 
western blots were run, and radiographic films created, as described in section 2.4.1.   
Results of the optimisation for the primary antibody, as documented in section 2.4.1.2, 
identified a more consistent staining, at the correct molecular weight (37kDa) with 
antibody 652 (Figure 4A). 
To confirm specificity of the 652 anti-clusterin antibody, western blots were run for the 
serum samples, one blot was incubated with the primary goat antibody against CLU; the 
other was incubated without the primary antibody. The presumed CLU protein band, 
visible at approximately 37kDa, was only identified following incubation with the 
primary antibody. This indicated that the CLU antibody detected a protein of the correct 
molecular weight. The absence of a protein band at this weight, without the primary 
antibody, implied specificity of the antibody to canine CLU, (Figure 4B).  
For each of the antibody optimisation experiments, both samples were run in 
quadruplicate, at differing protein concentrations. In order to determine optimal 
concentrations, aliquots of serum containing 2.5μg, 5μg, 10μg, and 20μg of protein, as 
determined via previous protein assay, were prepared and run as per section 2.4.1. 
Western blots were run, and examination of the resultant radiographic films revealed an 
optimum protein concentration for sample handing and band density, of 10μg of sample, 
(Figure 4C).  
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Figure 4: 
 
A) Western blot of control and MLSA pre-treatment serum samples, comparing 
different antibodies are shown for anti-clusterin antibodies, 991 and 652, both at 
1:10,000 dilutions. The position of the molecular weight marker (Mk) is indicated at 
48 and 37 kDa. A stronger, clearer protein band is seen with the CLU 652 antibody, 
at the predicted molecular weight of approximately 37kDa. 
 
B) Western blot of control and MLSA pre-treatment serum samples, incubated with and 
without primary anti-clusterin antibody 652, at a 1:10,000 dilution confirming CLU 
antibody 652 specificity. The position of the molecular weight marker (Mk) is 
indicated at 48 and 37 kDa. A clear protein band can be seen at approx. 37kDa in 
the presence of the primary anti-clusterin antibody and not present without the 
primary antibody. 
 
C) The intensity of the CLU signal is proportional to the amount of protein loaded onto 
the gel. Analysis of the protein intensity by Image J is shown graphically and there 
is indication of saturation with 20ug of protein, 10ug of protein was used in 
subsequent experiments.   
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 Clusterin expression in pilot samples 
Samples were initially selected from a bank of archived serum samples, using the 
selection criteria described in section 2.1. Samples consisted of; dogs with MLSA pre-
treatment (n=20) and healthy controls (n=20), (Table 2). Eight samples from each cohort 
were selected for western blot analysis, (Table 3) before experiments were expanded to 
include all 20 samples from each cohort. 
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Table 2) 
Signalment of pilot samples 
 Pre-treatment  
MLSA 
(n=20) 
 
Controls 
(n=20) 
p values 
Age (years) 
Median 
Range  
 
7 
2 - 12 
 
4 
0.75 - 7 
 
Mann Whitney U 
Test 
p < 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
9 
6 
2 
3 
 
4 
8 
1 
7 
 
Chi squared  
Fisher’s exact 
p > 0.05 
Stage: 
III 
IV 
V 
 
5 
8 
7 
 
N/A 
 
- 
Substage: 
a 
b 
 
6 
14 
 
N/A 
 
- 
Immunophenotype: 
B 
T  
Null 
 
8 
2 
1 
 
N/A 
 
-  
Breed:  
Airedale terrier   
Border collie  
Border terrier  
Boxer  
Bullmastiff  
Cairn terrier  
Cocker spaniel  
Crossbreed  
Doberman 
Flat-coated retriever 
German shepherd  
Golden retriever  
Gordon setter  
Greyhound 
Labrador retriever  
Patterdale terrier  
Springer spaniel  
Tibetan terrier  
 
1 
3 
1 
3 
1 
1 
1 
2 
0 
0 
1 
0 
1 
0 
1 
1 
2 
1 
 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
2 
4 
0 
2 
8 
0 
1 
0 
 
- 
 
  
 
44 
 
Table 3)  
Signalment of partial pilot group 
 Pre-treatment  
MLSA 
(n=8) 
 
Controls 
 (n=8) 
p values 
Age (years) 
Median 
Range  
 
6.5 
2 – 10 
 
3 
0.75 – 7 
 
Mann Whitney U 
Test 
p > 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
6 
2 
0 
0 
 
3 
4 
0 
1 
 
Chi squared  
Fisher’s exact 
p > 0.05 
Stage: 
III 
IV 
V 
 
4 
2 
2 
 
N/A 
 
- 
Substage: 
a 
b 
 
3 
5 
 
N/A 
 
- 
Immunophenotype: 
B 
T  
 
4 
1 
 
N/A 
 
-  
Breed:  
Border collie  
Boxer  
Cocker spaniel  
Crossbreed  
Flat-coated retriever 
German shepherd  
Golden retriever  
Labrador retriever  
Springer spaniel  
Tibetan terrier  
 
1 
1 
1 
2 
0 
1 
0 
0 
1 
1 
 
0 
0 
0 
1 
1 
2 
1 
3 
0 
0 
 
- 
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 Western blot on 18 well gel. 
Serum CLU concentrations of dogs with MLSA, pre-treatment (S, n=8) were compared 
to healthy controls (C, n=8), via western blot analysis, (Figure 5A). Single samples were 
loaded onto the gel in an alternating pattern, control sample then MLSA sample, repeated 
from left to right. Molecular weight protein markers were run in the first and last well of 
each gel. The median protein band density of the pre-treatment serum samples was 6697 
(range 1874 - 8043), compared to 6901 (range 4773 - 8736) for control samples, (Figure 
5B). There was no statistically significant difference between the two groups (p=0.51, 
Mann Whitney U test).   
 
 
Figure 5:  
 
A) Western blot analysis comparing serum CLU in pilot samples from dogs with 
MLSA pre-treatment (S1-S8) and healthy controls (C1-C8). 
  CLU 652 antibody at a 1:10,000 dilution.  
Mk denotes annotation of molecular weight protein marker, labelled at 37kDa.  
 
B) Scatter graphs comparing protein band density, depicting serum CLU levels, in 
pilot samples from dogs with MLSA pre-treatment (n=8) and healthy controls 
(n=8).  
Vertical scatter graphs showing data presented with median and interquartile 
range. 
Serum CLU was not significantly different between MLSA pre-treatment and 
healthy controls. 
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 Western blots run across two 26 well gels. 
Serum CLU concentrations of dogs with MLSA, pre-treatment (S, n=20) were then 
compared to healthy controls (C, n=20), via western blot analysis, (Figure 6). To 
facilitate the number of samples, two BioRad gels were run concurrently. Single samples 
were again loaded onto the gel in an alternating pattern, control sample then MLSA 
sample, repeated from left to right. Molecular weight protein markers were run in the first 
and last well of each gel. Eight samples chosen at random, four MLSA pre-treatment and 
four control samples were run in duplicate, appearing once on each gel. These samples 
were to serve as between gel control, due to the inherent variability than can occur 
between western blots. 
 
 
 
Figure 6:  
 
Western blots comparing serum CLU in pilot samples from dogs with MLSA pre-
treatment (S1-S20) and healthy controls (C1-C20), CLU 652 antibody at a 1:20,000 
dilution. 
Mk denotes annotation of molecular weight protein standard marker, labelled 37kDa. 
Four MLSA pre-treatment samples, S9-S12 and four control samples C9-C12 appear in 
duplicate, once on each gel. 
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Comparison between western blots is frequently problematic, due to potential differences 
in the final product. Experimental technique, due to human factors, equipment and 
environment could alter the final radiographic quality and hence the ultimate density of 
protein bands. To take this into account, the samples which were run in duplicate were 
used to produce a correction factor (×). The mean protein band density from duplicated 
samples on Gel a was divided by the mean protein band density from duplicated samples 
on Gel b to create correction factor ×. The remaining protein band density results from 
Gel b were each individually multiplied by × to give a corrected protein band density for 
those eight controls and eight MLSA samples.  
When the correction value was applied to protein band density results from Gel b, all 40 
samples could be directly compared. The median protein band density of the MLSA pre-
treatment serum samples was 2697 (range 778.6 - 5347), the median protein band density 
of the healthy control samples was 2589 (range 197 - 5377), (Figure 7).  
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Figure 7:  
 
Scatter graphs comparing protein band density, depicting serum CLU levels, comparing 
pilot samples from dogs with MLSA pre-treatment (n=20) and healthy controls (n=20). 
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was not significantly different between MLSA pre-treatment and healthy 
controls. 
 
There was no statistically significant difference in protein band density between MLSA 
pre-treatment samples and healthy controls (p=0.88, Mann Whitney U test).   
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Although using a correction factor allowed comparison between blots and accounted for 
individual experiment variation, it was deemed imprecise and as such not a reliable 
method of experimentation. Further direct comparisons were therefore confined to intra-
blot data, which limited sample numbers.  
 
 Clusterin - sample group one (unrelated samples) 
All samples were selected, using selection criteria as described in section 2.1, to create 
the first sample group, and generate three distinct sample cohorts.  
Sample group one consisted of 3 cohorts; dogs diagnosed with MLSA, pre-treatment (A, 
n=12), unrelated dogs with MLSA, in CR (B, n=12) and healthy control dogs (C, n=12). 
 
 Group signalment  
Signalment of the dogs in sample group one is summarised in Table 4.  
Of the pre-treatment MLSA samples (cohort A) median age was 8 years (range 5-12). 
Nine dogs were male (four entire, five neutered) and three were female (three entire). 
There were eight breeds represented, with border collie the most common, representing 
25% of the population; boxer and Labrador retriever followed, representing 16.7% each, 
of the group population. Eight dogs had stage V disease and four had stage IV disease; 
there were three dogs in substage a and nine in substage b, as determined by the WHO 
TNM classifications(Owen, 1980; Vail et al., 2013). Immunophenotype was known for 
8/12 (66.6%), there were seven dogs with B-cell LSA (87.5%) and one with T cell LSA 
(12.5%).  
Of the samples in CR (cohort B) median age was 7.5 years (range 4-12). Seven dogs were 
male (three entire, four neutered) and five were female (five neutered). There were eleven 
breeds represented, with border collie again the most common, representing 16.7% of the 
group population. Two dogs had stage V disease, 6/12 had stage IV disease, 3/12 stage 
III disease and 1/12 stage II disease. There were five dogs in substage a and seven in 
substage b. Immunophenotype was known for 10/12 cases (83.3%), with all dogs having 
B-cell LSA. 
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Of the healthy control dogs (cohort C), median age was 4 years (range 1-7). Five dogs 
were female (one entire, four neutered) and seven were male (three entire, four neutered). 
There were seven breeds represented, with Golden retriever and Labrador retriever the 
most common, each representing 25% of the control population. 
Signalment of the dogs with untreated and treated MLSA was similar. Median age did 
not differ significantly between cohort A (8 years) and B (7.5 years) groups, however the 
median age of the control dogs (4 years) was significantly younger than both MLSA, pre-
treatment and in CR (p<0.05, ANOVA, Bonferroni).  All cohorts were predominantly 
male, with no significant difference in sex or neuter status between the three (p>0.05, 
Chi-squared). Stage of disease at initial presentation (untreated) was higher in cohort A, 
with significantly more stage V disease in comparison to the cohort B (p<0.01, Fisher’s 
exact); there was no significant difference in substage. Immunophenotype was known in 
75% of cases overall (75%), with a higher proportion of B-cell LSA in cohort B, although 
this was not statistically significant (p>0.05, Fisher’s exact). 
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Table 4)  
Signalment of sample group one 
 Pre-
Treatment 
MLSA  
(A, n=12) 
CR 
MLSA 
(B, n=12) 
 
Control 
(C, n=12) 
 
p values 
Median Age (years) 
Range  
8  
5 - 12  
7.5 
4 - 12 
4 
1 - 7 
ANOVA 
p < 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
5 
3 
0 
 
3 
4 
0 
5 
 
3 
4 
1 
4 
 
Chi squared 
p > 0.05 
Stage: 
II 
III 
IV 
V 
 
0 
0 
4 
8 
 
1 
3 
6 
2 
 
N/A 
 
Chi squared 
p < 0.05 
Substage: 
a 
b 
 
3 
9 
 
5 
7 
 
N/A 
 
Fisher’s 
exact 
p > 0.05 
Immunophenotype: 
B 
T  
 
7 
1 
 
10 
0 
 
N/A 
 
Fisher’s 
exact 
p > 0.05 
Breed: 
Beagle  
Border collie 
Border terrier 
Boxer 
Cairn terrier 
Cavalier King Charles spaniel 
Cocker spaniel 
Crossbreed 
Dachshund 
Doberman pinscher 
Flat coated retriever 
German shepherd 
Golden retriever 
Gordon setter  
Greyhound 
Hungarian visla  
Jack Russel terrier 
Labrador retriever 
Tibetan terrier 
Whippet 
 
0 
3 
1 
2 
1 
1 
0 
1 
0 
0 
0 
0 
0 
1 
0 
0 
0 
2 
0 
0 
 
1 
2 
0 
0 
0 
0 
1 
1 
1 
0 
0 
1 
1 
0 
0 
1 
1 
0 
1 
1 
 
0 
0 
0 
0 
0 
0 
0 
1 
0 
1 
1 
2 
3 
0 
1 
0 
0 
3 
0 
0 
 
- 
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 Western Blot analysis 
Serum CLU concentrations, of the three cohorts, were initially compared by western blot 
analysis, on three separate western blots. Intra-blot comparison of protein band density 
was carried out. 
 
 Comparison of dogs with MLSA pre-treatment and healthy 
controls  
Serum samples from dogs with MLSA pre-treatment (A) were compared to control 
samples (C), via western blot analysis, (Figure 8A). Single samples were loaded onto the 
gel in an alternating pattern, MLSA sample then control sample, repeated from left to 
right. Molecular weight protein markers were run in the first and last well of each gel.  
The median protein band density of the MLSA pre-treatment serum samples was 11074 
(range 2885-19590) compared to 14699 (range 7324-20622) for control samples, (Figure 
8B).  
There was no statistically significant difference between the two groups (p=0.07, 
student’s t-test).  
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Figure 8:  
 
A) Western blot analysis comparing serum CLU in dogs with MLSA pre-treatment 
(A1-A12) and healthy controls (C1-C12). 
Mk denotes annotation of molecular weight protein standard marker, labelled at 
37kDa.   
 
B) Scatter graphs comparing protein band density, depicting serum CLU levels, 
comparing dogs with MLSA pre-treatment (A, n=12) and healthy controls (C, 
n=12). 
Vertical scatter graphs showing data presented with median and interquartile 
range. 
Serum CLU was not significantly different between MLSA pre-treatment and 
healthy controls. 
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 Comparison of dogs with MLSA in CR and healthy controls  
 Serum samples from dogs with MLSA in CR (B) were compared to control samples (C), 
via western blot analysis, (Figure 9A). Single samples were loaded onto the gel in an 
alternating pattern, MLSA CR sample then control sample, repeated from left to right. 
Molecular weight protein markers were run in the first and last well of each gel.  
The median protein band density of the serum samples from dogs in remission was 12654 
(range 10620-14756) compared to 13977 (range 9947-15863), for serum of control 
samples, (Figure 9B).  
There was no statistically significant difference between the two groups (p=0.15, 
student’s t-test).   
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Figure 9: 
 
A)  Western blot analysis comparing serum CLU in dogs with MLSA in CR (B1-
B12) and healthy controls (C1-C12). 
Mk denotes annotation of molecular weight protein standard marker, labelled at 
37kDa.  
 
B) Scatter graphs comparing protein band density, depicting serum CLU levels, 
comparing dogs with MLSA in CR (B, n=12), and healthy controls (C, n=12).  
Vertical scatter graphs showing data presented with median and interquartile 
range. 
Serum CLU was not significantly different between MLSA CR and healthy 
controls. 
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 Comparison of MLSA pre-treatment and CR  
Serum samples from dogs with MLSA pre-treatment (A) were compared to unrelated 
dogs with MLSA in CR (B), via western blot analysis, (Figure 10A). Single samples were 
loaded onto the gel in an alternating pattern, MLSA sample then CR sample, repeated 
from left to right. Molecular weight protein markers were run in the first and last well of 
each gel.  
The median protein band density of the pre-treatment serum samples (A) was 6503 (range 
2040-18247) compared to 11252 (range 6109-13343), for dogs in CR (B), (Figure 10B).  
There was no statistically significant difference between the two groups (p=0.38, 
student’s t-test). 
  
 
56 
 
 
 
 
 
Figure 10:  
 
A) Western blot analysis comparing serum CLU in dogs with MLSA pre-treatment 
(A1-A12) and unrelated dogs with MLSA in CR (B1-B12) 
Mk denotes annotation of molecular weight protein standard marker, labelled at 
37kDa.  
 
B) Scatter graphs comparing protein band density depicting serum CLU levels, 
comparing dogs with MLSA pre-treatment (A, n=12) with unrelated MLSA dogs, 
in CR (B, n=12). 
Vertical scatter graphs showing data presented with median and interquartile 
range. 
Serum CLU was not significantly different between MLSA pre-treatment and 
CR. 
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 Western blot results summary 
The three western blots were analysed independently, each comparing 12 diseased 
samples to 12 control samples. Intra-blot comparison of protein band density from the 
western blots comparing diseased and control samples (section 3.3.2.1 and 3.3.2.2) were 
suggestive of a trend for a lower CLU level in dogs with MSLA in comparison to controls. 
When performing statistical testing on results data however, there was no statistically 
significant difference between sample cohorts on any of the three western blots (p>0.05, 
student’s t-test). 
Inter-blot analysis was not performed due to the difficulties with interpretation and 
configuration of data (as discussed in section 3.2.2). However, each sample was run in 
duplicate, singly, on two separate western blots. The two separate protein band density 
results, one from each western blot, of all 36 samples were compared and a positive 
correlation between western blot results was found (Pearson’s r = 0.43), (Figure 11). 
While the numerical values of the samples from different gels are not directly comparable, 
the positive correlation gives confidence in the repeatability of results and highlighted the 
robust nature of the technique.  
 
 
Figure 11:  
 
Scatter graph with line of best fit, depicting correlation of samples on two separate 
western blots. 
Pearson’s r = 0.43 
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 ELISA Analysis  
For a more reproducible way of assessing CLU concentration, serum CLU was measured 
again, in the same 36 samples (Cohorts A, B and C) using a previously validated ELISA 
assay, as described in section 2.4.2, (Figure 12A). 
 
 Clusterin concentration 
Median serum CLU concentration in MLSA dogs, pre-treatment (A) was 53.8μg/ml 
(range 15.9 – 101.1), compared to dogs in CR (B) 67.0μg/ml (49.3-116.8), and 93.6μg/l 
(70.1- 120.1) in control samples (C), (Figure 12B). 
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Figure 12:  
A) Representative example of standard curve for ELISA data, generated using 
results from protein standards (4-128ng/ml). 
 
B) ELISA of serum CLU concentrations, comparing samples from three cohorts; 
dogs with MLSA pre-treatment (A, n=12), unrelated dogs with MLSA in CR (B, 
n=12) and healthy controls (C, n=12).  
Vertical scatter graphs showing data presented with median and interquartile 
range. 
Serum CLU was significantly lower in MLSA pre-treatment in comparison to 
controls, and MLSA CR in comparison to controls.  
*** p <0.001, * p<0.05, ANOVA. 
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There was a significant difference in the median serum CLU concentrations between the 
three groups, (ANOVA, p=0.0008). Bonferroni’s multiple comparison test showed a 
significant difference when individual cohorts were also compared. Serum CLU was 
significantly lower (p=0.0006) in MLSA pre-treatment compared with controls, and 
significantly lower (p=0.0036) in MLSA in CR, in comparison to controls. When looking 
at the two MLSA cohorts, there was no significant difference in serum CLU levels 
between dogs with MLSA, prior to treatment and in remission.   
 
 Comparison of Western Blot and ELISA 
Expression data from the 36 samples run by western blot analysis and the ELISA 
concentrations were directly compared and showed a significant correlation (Pearson’s r 
= 0.47), (Figure 13). This suggested that the two methods were comparable and gave 
confidence in the perceived repeatability of results.  
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Figure 13:  
 
Scatter graph with line of best fit, depicting correlation of samples from western blots 
and ELISA. 
Pearson’s r = 0.47 
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 Clusterin - sample group two (paired samples) 
To account for individual variation between dogs with MLSA, serum CLU concentrations 
were compared in a further 18 dogs. Samples were again selected using selection criteria 
in 2.1, and the ELISA performed as described in section 2.4.2. The serum CLU 
concentrations from paired samples, from the same dog, at time of diagnosis (pre-
treatment) and again in CR, were measured and compared. 
Sample group two consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment 
(n=18), and in CR (n=18), i.e. paired samples from the same individuals. 
 
 Group signalment 
Signalment of the dogs in sample group two is summarised in Table 5.  
Of the eighteen dogs the median age was 9 years (range 5-14). Nine dogs were female 
(two entire, seven neutered) and nine males (four entire, five neutered). There were 
thirteen breeds represented, with golden retriever the most common, representing 37.5% 
of the population, border collies and Labradors followed, representing 11% each of the 
group population.  
Three dogs (16.6%) had stage III disease, nine (50%) stage IV and six (33.3%) stage V. 
Eleven (61%) dogs were substage a and seven (39%) substage b, as determined by the 
WHO classification (Owen, 1980; Vail et al., 2013). Immunophenotype was known for 
66% of cases, with ten cases (83%) of B cell LSA and two cases of T cell LSA (16.6%).  
Group signalment and MLSA phenotype were similar to that of the previously assessed 
samples although direct statistical comparisons between groups were not performed.  
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Table 5)  
Signalment of sample group two - paired samples   
 Paired 
Samples 
(n=18) 
 
Median Age (years) 
Range  
9 
5 - 14  
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
5 
2 
7 
Stage: 
II 
III 
IV 
V 
 
0 
3 
9 
6 
Substage: 
a 
b 
 
11 
7 
Immunophenotype: 
B 
T  
 
10 
2 
Breed:  
Border collie 
Cocker spaniel 
Crossbreed 
German shepherd 
Golden retriever 
Jack Russel terrier 
Labrador retriever 
Parsons terrier 
Shih Tzu 
Spinone  
Tibetan terrier 
West Highland White terrier  
Yorkshire terrier 
 
3 
1 
1 
1 
3 
1 
2 
1 
1 
1 
1 
1 
1 
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 Clusterin concentration 
Median serum CLU concentration in samples from dogs prior to treatment was 50.4μg/ml 
(range 36.1 –118.1).  Median serum CLU concentration from the same dogs in CR was 
51.3μg/ml (34.0 – 141.1), (Figure 14). 
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Figure 14:  
ELISA of serum CLU concentrations, comparing paired samples from dogs with MLSA 
pre-treatment (n=18) and at time of CR (n=18).  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was not significantly different between MLSA pre-treatment and CR.  
 
 
 Statistical analysis  
There was no significant difference in serum CLU concentrations between the two 
cohorts, prior to treatment and in CR (p=0.83, Wilcoxon signed rank test).  
Subjective assessment of results showed no consistent trends in individual serum CLU 
concentrations; 7/18 (38.9%) dogs had increased CLU concentrations, 7/18 (38.9%) 
decreased and 4/18 (22.2%) remained relatively static when dogs achieved remission 
(Figure 13). 
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Figure 15: 
 
Line graph illustrating changes in individual CLU concentration when CR is achieved, 
showing no significant trend for increasing or decreasing levels. 
Serum CLU was not significantly different between MLSA pre-treatment and CR.  
 
 Clusterin - sample group three (age matched)  
There was a significant difference in age between dogs with MLSA and controls, in the 
initial samples. In an attempt to eliminate bias from the results, a further cohort of serum 
samples was selected. Using selection criteria in section 2.1, samples were preferentially 
chosen to represent a younger cohort of dogs diagnosed with MLSA, pre-treatment. 
Further samples were also selected for the control population, with preference for control 
samples given to samples from dogs over four years old. ELISA analysis was performed, 
as described in section 2.4.2, on the new cohorts of samples. 
Sample group three consisted of 2 cohorts; dogs diagnosed with MLSA, pre-treatment 
(n=18) and healthy control dogs (n=18). Samples for group three were intentionally 
selected to form age matched cohorts. 
 
 Group signalment 
Signalment of the dogs in sample group three is summarised in Table 6.  
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Eighteen treatment naïve dogs with MLSA were compared to 18 healthy controls. The 
median age of the dogs with MLSA was 6 years (range 3-7). Six dogs were female (one 
entire, five neutered) and 12 males (four entire, eight neutered). There were thirteen 
breeds represented, with golden retriever and border collie the most common, each 
representing 16.7% of the population.  
 There were seven dogs (38.8%) with stage III disease, eight (44.4%) with stage IV and 
three (16.6%) with stage V disease. Seven (39%) dogs were classified in substage a and 
eleven (61%) substage b, as determined by the WHO TNM classifications (Owen, 1980; 
Vail et al., 2013). Immunophenotype was known for 77.7% of cases, with five cases 
(35.7%) of B cell LSA and nine T cell LSA (64.3%).  
Of the healthy control dogs, median age was 5 years (range 4-7). Nine dogs were female 
(one entire, eight neutered) and nine were male (four entire, five neutered). There were 
seven breeds represented, with greyhound the most common, accounting for 44% of the 
control population. 
The age, sex and neuter status were not significantly different between the two groups.  
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Table 6)  
Signalment of sample group three - age matched samples 
 Pre-treatment  
MLSA 
(n=18) 
 
Controls   
(n=18) 
p values 
Age (years) 
Median 
Range  
 
6 
3 - 7 
 
5 
4 - 7 
 
Mann Whitney U 
Test 
p > 0.05 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
4 
8 
1 
5 
 
4 
5 
1 
8 
 
Chi squared  
Fisher’s exact 
p > 0.05 
Stage: 
II 
III 
IV 
V 
 
0 
7 
8 
3 
 
N/A 
 
- 
Substage: 
a 
b 
 
7 
11 
 
N/A 
 
- 
Immunophenotype: 
B 
T  
 
5 
9 
 
N/A 
 
-  
Breed:  
Bernese mountain dog 
Border collie 
Boxer 
Bullmastiff 
Cocker spaniel 
Crossbreed 
Doberman 
Dogue de Bordeaux 
Flat-coated retriever 
Golden retriever 
Greyhound 
Jack Russell terrier 
Labrador retriever 
Lurcher 
Shetland sheepdog 
Springer spaniel 
Tibetan terrier 
Weimaraner 
 
1 
3 
1 
1 
2 
1 
0 
1 
1 
3 
0 
1 
0 
1 
1 
0 
1 
0 
 
0 
0 
0 
0 
0 
1 
1 
0 
0 
2 
8 
0 
4 
0 
0 
1 
0 
1 
 
- 
  
 
67 
 
 Clusterin concentration 
The median serum CLU concentration in pre-treatment MLSA dogs was 58.3μg/ml 
(range 30.5 – 137.4) compared to 98.9μg/ml (range 73.2 – 141.0) from healthy controls, 
(Figure 16).   
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Figure 16:  
 
ELISA of serum CLU concentrations, comparing age matched samples from dogs with 
MLSA pre-treatment (n=18) and healthy controls (n=18).  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was significantly lower in MLSA pre-treatment in comparison to controls 
***p<0 .001, Mann Whitney U test. 
 
 Statistical analysis  
There remained a significant difference in the CLU concentration between dogs with 
MLSA, pre-treatment, and healthy controls. The median serum CLU concentration in pre-
treatment MLSA dogs was significantly lower than healthy controls (p=0.0002, Mann 
Whitney U test).   
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 Clusterin - combined ELISA data 
The CLU concentrations were determined using a commercial immunoassay (BioVendor 
Ltd, UK). The assay was previously validated, internally by BioVendor and 
independently as part of an investigation into urinary CLU (García-Martínez et al., 2012). 
Internal validation, through BioVendor, identified an acceptable between-run 
comparability, with an inter‐assay coefficient of variance (n = 8) of 6.2%. Whilst external 
validation also showed an acceptable inter-assay comparability with inter-assay 
coefficient of variance of 14.2-16.1% (García-Martínez et al., 2012).  
All three ELISA plates were run following the same protocol, in the same conditions 
(section 2.4.2 and Appendix 4), at separate times. Since the CLU assay is a commercially 
validated assay (BioVendor), the individual CLU concentrations across all ELISAs 
should be directly comparable. Additionally, reference quality controls for intra-assay 
assurance (high and low, supplied with each ELISA kit) were also run on each ELISA 
plate and gave values consistent with the concentrations reported for these controls (see 
section 4.3). Inter-assay coefficient of variance for the quality control samples varied 
from 8.9-16.7%.  
 
 Duplicated ELISA samples  
During sample selection (section 2.1) some samples, from dogs with MLSA pre-
treatment, were found to fulfil criteria for multiple sample groups. Six individual samples 
were deliberately included in both sample group two and sample group three, thus two 
separate CLU concentrations were generated for each of these samples, on separate 
ELISA plates.  
CLU concentrations were significantly higher (p<0.05, Wilcoxon signed rank test) in the 
six samples when run for the second time, as part of sample group three (on ELISA plate 
three). The inter-run percentage difference between the mean CLU concentrations from 
the two plates varied from 2% to 40.1%. When the individual sample results were 
analysed, the coefficient of variance between the results from the two ELISA plates varied 
from 5.9-19.4% with only one of the six samples reporting a coefficient of variance less 
than 6.2%, the inter‐assay coefficient of variance, reported by BioVendor (Figure 17).  
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Figure 17: 
  
Line graph of ELISA data from two separate ELISA plates, run at different time points.  
Graph illustrates CLU concentrations from six individual samples run once on each 
ELISA plate.  
Serum CLU was significantly higher when run on ELISA plate 3  
*p<0.05 Wilcoxon signed rank test. 
 
 
Unexpectedly, based on the ELISA kit data provided, there was a significant difference 
in CLU concentrations when run on separate ELISA plates. Three samples had an 
acceptable degree of variation, with 5.9%, 6.3% and 11.5% variation, two samples had a 
higher coefficient of variance at 14.2% and 16%, with one sample set resulting in a 
coefficient of variance of 19.4%. Although these differences are greater than anticipated, 
there were only a small number of samples which appeared on two ELISA plates allowing 
for analysis. It was assumed that any drift between plates would be consistent, influencing 
both MLSA samples and healthy controls. Thus, notwithstanding these limitations, it was 
still considered of value to assess all ELISA results in a combined analysis.  
Results from all sample groups were therefore combined to assess serum CLU 
concentrations in 42 individual dogs with MLSA pre-treatment and 30 individual control 
samples. For any samples run on more than one ELISA, only the initial CLU values from 
the first ELISA analysis were used.  
 
 
70 
 
 
 Group signalment 
Signalment of the dogs in the combined sample group is summarised in Table 7.  
The median age of the 42 pre-treatment samples was 7 years (range 3-14). There was a 
male preponderance with fifteen female dogs (five entire, 10 neutered) and 27 male dogs 
(10 entire, 17 neutered). There was a wide range of breeds represented, with border collie 
accounting for 19% of samples (8/42). Labrador and golden retriever each accounted for 
9.5% of samples, with four dogs from each breed. There were three each of crossbreed 
and boxer dog (7%), and two cocker spaniels (4.8%). There were seven terriers, one each 
of Parsons, border, West Highland, Yorkshire, Cairn, Jack Russell terrier and Tibetan. 
And one each of German shepherd, shih tzu, cavalier King Charles spaniel, Italian 
Spinone, flat-coated retriever, bullmastiff, Shetland sheepdog, Bernese mountain dog, 
lurcher, Gordon setter and Dogue de Bordeaux.  
Eight of the 42 dogs were stage III (19%), 19 (45%) stage IV and 15 (36%) stage V. 
Seventeen (40.5%) dogs were substage a and 25 (59.5%) substage b. Immunophenotype 
was known for 69% of cases, with 19 cases (65.5%) of B cell and 10 cases of T cell LSA 
(34.5%).  
The median age of the 30 healthy control dogs was 5 years (range 1-7), significantly lower 
than the diseased population (p<0.05 Mann Whitney test). Sex was more evenly 
distributed in the control population with 14 female dogs (two entire, 12 neutered) and 
sixteen male dogs (seven entire, nine neutered). The sex and neuter status of the two 
groups did not differ significantly (p>0.05, Chi-squared, Fisher’s exact). There were nine 
breeds represented with nine greyhounds, seven Labradors and five golden retrievers 
representing the majority of the population. There were also two from each of 
crossbreeds, Doberman pinschers and German shepherd, and one each of Weimaraner, 
springer spaniel and flat-coated retriever. While not compared statistically, the breed 
distribution of the two groups was notably different, due to the control population 
comprising of blood donors.  
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Table 7)  
Signalment of combined sample group 
 Pre-treatment  
MLSA 
(n=42) 
 
Controls  
(n=30) 
p values 
Median Age (years) 
Range  
7 
3 - 14 
5 
1 - 7 
Mann Whitney U 
Test 
p < 0.01 
Sex:  
Male entire 
Male neutered 
Female entire 
Female neutered 
 
10 
17 
5 
10 
 
7 
9 
2 
12 
 
Chi squared  
Fisher’s exact 
p > 0.05 
Stage: 
III 
IV 
V 
 
8 
19 
15 
 
N/A 
 
- 
Substage: 
a 
b 
 
17 
25 
 
N/A 
 
- 
Immunophenotype: 
B 
T  
 
19 
10 
 
N/A 
 
-  
Breed:  
Bernese mountain dog 
Border collie 
Border terrier 
Boxer 
Bullmastiff 
Cairn terrier 
Cavalier King Charles Spaniel 
Cocker spaniel 
Crossbreed 
Doberman 
Dogue de Bordeaux 
Flat-coated retriever 
German shepherd 
Golden retriever 
Gordon setter 
Greyhound 
Jack Russell terrier 
Labrador retriever 
Lurcher 
Parsons terrier 
Shetland sheepdog 
Shih Tzu 
Spinone 
Springer spaniel 
Tibetan terrier 
Weimaraner 
West Highland White terrier  
Yorkshire terrier 
 
1 
8 
1 
3 
1 
1 
1 
2 
3 
0 
1 
1 
1 
4 
1 
0 
1 
4 
1 
1 
1 
1 
1 
0 
1 
0 
1 
1 
 
0 
0 
0 
0 
0 
0 
0 
0 
2 
2 
0 
1 
2 
5 
0 
9 
0 
7 
0 
0 
0 
0 
0 
1 
0 
1 
0 
0 
 
- 
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 Clusterin concentration 
Median serum CLU concentration from samples taken from dogs with MLSA prior to 
treatment was 51.9μg/ml (range 15.9 – 135.6). Median serum CLU from healthy control 
samples was 97.1μg/ml (range 70.1 – 141.0), (Figure 18). There was a significant 
difference noted in serum CLU concentrations in samples from diseased and control dogs, 
with serum CLU significantly lower in dogs with MLSA pre-treatment in comparison to 
healthy controls (p<0.0001, Mann Whitney U test).  
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Figure 18:  
 
Combined ELISA data, of serum CLU concentrations comparing dogs with MLSA pre-
treatment (n=42) and healthy controls (n=30).  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was significantly lower in MLSA pre-treatment in comparison to controls 
****p<0 .0001, Mann Whitney U test. 
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Serum CLU concentrations from dogs with MLSA were further separated into stage, 
substage and by immunophenotype. Median serum CLU concentration in samples from 
dogs with stage III disease was 47.4μg/ml (36.2 - 65.3). Median serum CLU 
concentrations from dogs with stage IV disease was 52.3μg/ml (36.1 – 135.6) and from 
stage V disease, 55.2μg/ml (15.9-118.1), (Figure 19). There was no significant difference 
noted in CLU concentrations between dogs in different stages of disease (p>0.05, 
Kruskal-Wallis).  
 
 
 
III IV V
0
50
100
150
C
lu
s
te
ri
n
 C
o
n
c
e
n
tr
a
ti
o
n
(u
g
/m
l)
 
 
Figure 19:  
 
Combined ELISA data, comparing pre-treatment serum CLU concentrations in dogs with 
MLSA in stage III, IV and V disease.  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was not significantly different between different stages of MLSA pre-
treatment.  
 
Median serum concentrations from serum samples from dogs in substage a was 47.6μg/ml 
(36.1 - 91.2) and substage b, 55.2μg/ml (15.9 - 135.6), (Figure 20). There was no 
significant difference in CLU concentrations in different substage of disease (p>0.05, 
Mann Whitney U test). 
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Figure 20:  
 
Combined ELISA data, comparing pre-treatment serum CLU concentrations in dogs with 
MLSA in substage a and substage b.  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was not significantly different between different substages of MLSA pre-
treatment.  
 
Median serum CLU concentration for samples from dogs with B cell LSA was 51.5μg/ml 
(15.9 – 101.1), and T cell LSA 65.0μg/ml (30.5 – 135.6), (Figure 21). There was no 
significant difference in serum CLU concentrations based on immunophenotype, 
(p>0.05, student’s t-test). 
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Figure 21:  
 
Combined ELISA data, comparing pre-treatment serum CLU concentrations in dogs with 
B-cell LSA and T-cell LSA.  
Vertical scatter graphs showing data presented with median and interquartile range. 
Serum CLU was not significantly different between different immunophenotypes of MLSA 
pre-treatment.  
 
 
 CLU concentration in controls 
The median serum CLU concentration in healthy control samples was 97.1μg/ml (range 
70.1 – 141.0), significantly higher than dogs with MLSA pre-treatment (p<0.0001, Mann 
Whitney U test). When data from all ELISA plates was combined, there remained a 
significant difference in age between the control and MLSA populations, with control 
dogs significantly younger (p<0.05, Mann Whitney U test).  
When considering the control population alone, serum CLU concentrations did not vary 
significantly in relation to age (p=0.742, univariate analysis).  And when comparing the 
control and MLSA population, on multivariate analysis, when disease status is taken into 
account, CLU did not vary significantly with regard to age (p=0.33, multivariate 
analysis). 
  
 
76 
 
4 Discussion 
In 2013, the serum proteome of three dogs with LSA, was characterised via serum protein 
electrophoresis and mass spectrometry (Atherton et al., 2013a), identifying a CLU 
precursor in the alpha-2 band of the proteome of one dog, which was absent in two healthy 
controls. This finding led to speculation that CLU may have a role in canine LSA. The 
research undertaken in this thesis identified the presence of the CLU protein, using 
Western Blot analysis and ELISA, in all canine serum samples tested. 
 
 Clusterin 
The primary aim of the thesis was to evaluate whether serum CLU expression differed 
significantly between those dogs with HG MLSA, and a healthy control population, and 
therefore had potential as useful diagnostic tool. Serum CLU levels in MLSA samples 
both pre-treatment and in CR, were consistently lower than that of a healthy control 
population, although statistically significant differences were detected only with the 
ELISA method. Although marked individual variation in CLU levels existed, results were 
suggestive of a possible down regulation in CLU activity in canine MLSA, however the 
degree of overlap with the healthy control population limits the potential of serum CLU 
measurement as a diagnostic tool. 
 
 Serum clusterin in MLSA  
Serum CLU concentrations were significantly lower in dogs with MLSA, pre-treatment, 
in comparison to healthy controls. While this finding was unexpected, compared to the 
original hypothesis based on a previous pilot study, multiple investigations, using 
different experimental techniques, demonstrated repeatable results. Additionally, even 
where potential differences were not statistically significant, there was a trend for lower 
CLU in MLSA samples than healthy controls.  
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Atherton et al. (2013a) previously identified a CLU precursor in the serum of a dog with 
high grade multicentric lymphoma (MLSA), and the absence of CLU in serum from two 
healthy controls, as determined by mass spectrometry (Atherton et al., 2013a, 2013b). 
While western blot analysis and ELISA identified serum CLU at varying concentrations 
in all samples, MLSA and healthy controls. The discordance in results may be due to the 
small number of samples originally assessed through mass spectrometry. Serum CLU was 
highly variable across individuals, both with MLSA and controls, and type II error may 
have led to a non-representative sample cohort, when initial mass spectrometry data 
consisted of samples from five dogs. Additionally, while present in all samples assessed 
via ELISA, CLU concentrations were low, measured in μg/ml. When analysing the serum 
proteome, with median total protein values of 64g/L, it is possible that CLU and CLU 
precursors were overshadowed by an abundance of other proteins.  
Since the original observation was based on a single MLSA case and two controls, using 
a qualitative rather than quantitative proteomic approach (Atherton et al., 2013a), the 
current findings, using two different methods, western blot analysis and ELISA, can be 
considered more reliable.  
CLU is an extracellular chaperone protein, important in stabilising protein folding, 
correcting misfolded proteins, and facilitating protein clearance (Humphreys et al., 1999; 
Wilson et al., 2000, 2017; Trougakos et al., 2009a; Wyatt et al., 2009, 2010). Multiple 
studies (Michel et al., 1997; Humphreys et al., 1999; Wyatt et al., 2009; Wilson et al., 
2017) describe an increase in CLU expression in response to cell stress or insult. But 
reduced levels of CLU and subsequent loss of the chaperone function may play an 
important role in tumourigenesis (Scaltriti et al., 2004; Shannan et al., 2006; Rizzi et al., 
2008, 2010). 
CLU levels have previously been assessed in human lymphoid neoplasia, most frequently 
via IHC. While not directly comparable, due to different methodologies used,  the low 
CLU levels detected in MLSA serum, are consistent with human literature reports of low 
or absent CLU levels in B-cell and T-cell LSA tissues, with the exception of anaplastic 
large cell LSA (Wellmann et al., 2000; Saffer et al., 2002; Nascimento et al., 2004). 
Saffer et al. (2002) identified cytoplasmic CLU expression on IHC in 35% of lymphoid 
neoplasia assessed; but only present in a small subset (12%) of DLBCL, and 7% of 
peripheral T-cell LSA cases. Additionally CLU levels were low in the Toledo DLBCL 
cell line when compared to healthy B lymphocytes (Coletta et al., 2012).  
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While immunophenotype was only known in 69% of the MLSA population, the majority 
(65%) were B-cell, presumed DLBCL, although definitive classification was not 
performed since histopathology was not obtained for most cases. When comparing to 
human studies, it is to be expected that CLU levels would be low in canine DLBCL. In 
the current study serum CLU did not differ significantly with immunophenotype, 
although sample sizes were small. Since most cases were diagnosed cytologically, 
immunophenotyping was performed primarily via PARR analysis, rather than gold 
standard IHC or preferred flow cytometry, however this is unlikely to have impacted on 
the results. While not considered to be gold standard, PARR is highly specific for 
identification of B or T cell gene rearrangements, thus false positive results are unlikely 
(Thalheim et al., 2013; Waugh et al., 2016).   
Given that serum CLU was significantly lower in canine MLSA than healthy controls, 
there were considerations as to whether a higher tumour burden/WHO stage of disease 
may have even lower serum CLU concentrations. No significant difference with WHO 
stage was detected, however, the lack of significant difference between different stages 
of disease may represent a type II error, due to the small sample numbers, and only 8 dogs 
with stage III disease. Additionally, as staging was not standardised, and did not always 
include cytology of the liver, spleen or bone marrow, there would be the possibility of 
stage migration within the sample population. Similarly, there was no significant 
difference between MLSA patients presenting with clinical signs (substage b), and those 
without clinical signs, (substage a). 
When directly comparing all MSLA pre-treatment samples with healthy controls, a serum 
CLU concentration of <69.2μg/ml had 100% specificity for disease (Appendix 6). 
However, over 20% of the MLSA population had CLU serum concentrations >69μg/ml 
(sensitivity 78% for detection of disease at CLU concentrations <69.2μg/ml). The 
receiver operating characteristic curve, (ROC curve) identified the highest likelihood of 
disease (likelihood ratio, 24.29), at CLU concentrations <70.42μg/ml, with this cut off 
having diagnostic sensitivity of 81% and specificity of 96.7%.  
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Individual CLU concentrations showed wide variation within the MLSA cohorts. Serum 
CLU in pre-treatment MLSA, across separate ELISA plates, ranged from 15.9μg/ml to 
135.6μg/ml, and significantly overlapped with healthy controls which ranged from 70.1- 
141.0μg/ml. This overlap and relative lack of sensitivity in detecting disease (in 
comparison to currently available diagnostics), limits the use of CLU as a diagnostic 
biomarker for MLSA.  
 
 Serum clusterin in MLSA, at time of CR 
The second aim of this thesis was to determine whether serum CLU expression differed 
significantly following successful treatment and induction of remission, and therefore had 
potential as a monitoring tool, as a marker of remission, early relapse or treatment failure. 
This was attempted firstly by comparing MLSA dogs in CR to healthy controls and 
secondly pre-treatment MLSA dogs to those in CR. 
 Serum CLU in MLSA(CR) in comparison to healthy controls  
Serum CLU concentrations were still significantly lower in dogs with MLSA, at time of 
CR, in comparison to healthy controls. It was hypothesised, that having been significantly 
lower in MLSA at time of diagnosis, CLU levels would normalise following successful 
treatment and may not differ from control dogs. Serum CLU levels were assessed in 
MLSA patients following 4-6 weeks of a CHOP based chemotherapy. While patients 
were evaluated as having achieved CR on the basis of clinical examination, no molecular 
testing or cytological evaluation for MRD was carried out. MRD testing has been shown 
to reach a nadir, following multidrug chemotherapy, between 4 and 17 weeks, and 
remains low until the end of the chemotherapy protocol at week 25 (Yamazaki et al., 
2010). It is possible that patients were not in complete molecular remission, or that re-
evaluation was performed too early. While 4-6 weeks should have been sufficient to 
assess remission on the basis of clinical signs, it could not be excluded that some patients 
continued to carry a burden of disease, thus causing the low CLU levels which were noted. 
Evaluation at additional points throughout treatment, including the end of the 
chemotherapy protocol and at time of relapse would better determine the relationship 
between CLU levels and disease status. With additional time, it is possible that CLU 
levels in MLSA patients would increase, with the achievement of clinical remission, to 
the level to healthy controls.  
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The CLU protein has a relatively short half-life (Rizzi et al., 2009a), it is possible that the 
ongoing inflammatory state caused by disease and concurrent chemotherapy treatment 
facilitated increased protein turnover, reducing the circulating CLU levels in the CR 
patients. MLSA patients show low levels of serum CLU at time of diagnosis, and 
downregulation of the CLU protein, which may have facilitated the initial 
tumourigenesis, may not be not rectified by chemotherapy treatment. It could be 
postulated that patients will continue to show low serum CLU levels following a diagnosis 
of MLSA, regardless of treatment protocol, time from treatment or remission status.   
 Comparing serum CLU in MLSA pre-treatment and CR 
Serum CLU concentrations were not significantly different between dogs with MLSA, 
prior to treatment, and those in CR, following 4-6 weeks of chemotherapy. Due to the 
wide variation in individual serum CLU levels, paired samples from the same dog with 
MLSA prior to treatment and once in CR were also evaluated, with no significant 
difference in individual serum CLU levels following treatment, and no significant trend 
for increasing or decreasing serum CLU.  
Doxorubicin has been shown to upregulate CLU, produced by HL and DLBCL (Toledo) 
cell lines, in vitro (Frazzi et al., 2011; Coletta et al., 2012). Most patients received 
doxorubicin as part of their chemotherapy protocol (week 4 of CHOP), with substitutions 
for mitoxantrone made if cardiac pathology was noted on echocardiography scanning. 
Patients who received mitoxantrone were not separately evaluated. This may have 
impacted results, as the effects of mitoxantrone chemotherapy on CLU levels is unknown. 
Additionally, there were a portion of patients, also not separately evaluated, deemed in 
CR at week 4 evaluation, prior to their doxorubicin chemotherapy. These patients would 
not have received doxorubicin at the time of their serum sampling. These discrepancies 
within the study population may account for the lack of significant difference in CLU 
levels between the MLSA and MLSA CR samples.  
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The increased CLU in the Toledo cell line (Coletta et al., 2012) occurs in conjunction 
with an inhibition of cell growth, and causing death through necrosis and apoptosis, thus 
it could be hypothesised that CLU increases following cell death. However, the same 
study showed an increase in CLU following Rituximab administration, which did not 
induce apoptosis. CLU was shown to increase in a dose dependent fashion (Frazzi et al., 
2011), thus it may be that a single dose of doxorubicin, at a 30mg/m2 dose (as per the 
CHOP protocol, Appendix 2) was insufficient to impact CLU levels. However these in 
vitro studies (Frazzi et al., 2011; Coletta et al., 2012) would indicate that treatment regime 
could influence the levels of circulating CLU at specific time points.  
Individual serum CLU concentration in MLSA patients following treatment was variable, 
with increased, decreased and static CLU concentrations noted following CR. Similar 
variation in serum CLU has been reported in a small subset of human patients with HL 
following treatment with chemotherapy (Frazzi et al., 2011). In that study of 18 HL 
patients, CLU levels increased in 39%, decreased in 28%, and remained static in 33%. 
There are similarities to the population of this thesis, where there was no trend for 
increasing or decreasing serum CLU levels in dogs who achieved remission following 
treatment. In the HL study, PET2 analysis performed following two cycles of 
chemotherapy appeared to correlate with CLU levels i.e. those patients PET2 negative 
and free from detectable disease, had decreased CLU detected in peripheral blood 
samples, while CLU levels in those who were PET2 positive, with an ongoing disease 
burden, increased (Frazzi et al., 2011), although CLU levels in some patients remained 
static following treatment, regardless of PET2 status (Frazzi et al., 2011).  
There was not a significant difference in CLU levels in MLSA pre-treatment and CR, 
thus CLU levels cannot be used as a marker for remission or relapse. However, it cannot 
be excluded that a relative change in individual CLU level could act as a prognostic or 
predictive marker for remission, relapse or prognosis following chemotherapy. 
Evaluation of this would require larger sample numbers, standardised treatment protocols 
to mitigate the effects of chemotherapeutics on CLU levels, and definitive evaluation of 
remission status via repeat staging and detection of MRD. 
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 Population factors  
Serum CLU was identified, in varying quantities, in both MLSA populations and the 
healthy control samples, conflicting with previous reports of the characterisation of the 
canine proteome (Atherton et al., 2013a, 2013b; Fonghem et al., 2017). While implicated 
in tumourigenesis, CLU has also been identified in a wide array of normal physiological 
and pathological processes, including cell stress, regulation of cell death and the aging 
process (Trougakos et al., 2002; Shannan et al., 2006; Wilson et al., 2017). Thus, the 
presence of CLU in healthy canine serum, while not found in the initial characterisation 
of the canine proteome, could be explained through normal cell turnover and the aging 
process.  
In humans CLU expression increases with age (Mondello et al., 1999; Trougakos et al., 
2002, 2006), although, similar to the canine population in this thesis, significant 
individual variation exists. The possible impact of age on CLU levels prompted further 
evaluation in this study, using age matched MLSA and control samples, for sample group 
three. When cohorts were age matched there remained a highly significant difference in 
serum CLU levels, with serum CLU significantly lower in MLSA in comparison to 
controls.  Additionally, when evaluating the combined data, multivariate analysis showed 
that the only factor which held significance for CLU concentration was MLSA disease 
status. Within the healthy control population serum CLU concentrations also did not vary 
significantly in relation to age, although this may in part be due to small sample size and 
overall narrow age range (1-7 years).  
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The CLU protein is described as well conserved (Michel et al., 1997; Calero et al., 1999; 
Wilson et al., 2000), with similar variants across species. Occasional studies refer to 
levels of other apolipoproteins (e.g. A, C and E) varying with race and ethnicity (Heiss et 
al., 1984; Brouwer et al., 2000). One study evaluating CLU determined coding variants 
and polymorphisms within exons of the CLU gene, which were more frequent in African-
American than Hispanics and rare in Caucasians (Tycko et al., 1996). While the MLSA 
population had a wide variety of breeds, predominated by dogs predisposed to LSA 
(Edwards et al., 2003; Dobson, 2012), the control population was heavily weighted 
towards large breed dogs. Greyhounds and retrievers accounted for over 70% of the 
control population, with greyhounds comprising 30% of all healthy controls. It is known 
that the haematological and biochemical parameters of greyhounds can vary significantly 
(Zaldívar-López et al., 2011) from that of the general canine population. With no known 
canine serum CLU reference range, it is not possible to know if greyhounds could have 
aberrant serum CLU levels. The lack of breed heterogeneity within the control population 
may have adversely impacted results.  
Additionally, since the control population were blood donors, the mean body weight of 
the control group was higher than that of the MLSA population. Studies have shown that 
both human and canine circulating CLU levels are positively correlated with body mass 
index and obesity (Won et al., 2014), with decreasing CLU correlating with weight loss 
(Tvarijonaviciute et al., 2012, 2013). Whether higher serum CLU levels would be 
expected in dogs with a higher lean body weight is unknown. The effects of obesity on 
CLU levels may be due to the chronic inflammatory state which obesity conveys (Barić 
Rafaj et al., 2017), rather than directly linked to lean body mass. The body condition 
scores of both MLSA and control dogs were not available for analysis.  
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The sample population in the present study was varied and representative of a portion of 
patients referred to Glasgow University Small Animal Hospital. However, samples may 
not be representative of the wider population. Samples were selected based on sample 
age, storage conditions, sample quality and stage of disease, rather than selected at 
random, thus unconscious bias may have impacted the results. It remains possible that 
results of this study may represent type I error, a false positive result and rejection of a 
true null hypothesis. However, notwithstanding these potential factors and while the 
sample size was small, there was a statistically significant difference in CLU 
concentration between dogs with MLSA prior to treatment and healthy controls, although 
this does not rule out the possibility of an aberrant population.  
 
 Techniques 
All of the techniques used in this thesis were subject to the variations that are normally 
encountered by multi-step methodologies associated with protein analysis. Typically, 
these may include, sample handling, pipetting accuracy and repeatability, washing 
regimes for western blots and ELISAs, and sample integrity due to freeze/thaw cycles. In 
order to limit variability and maintain an empirical consistency, the author of this thesis 
was directly responsible for sample handling and execution for all experiments with the 
inclusion of appropriate inter and intra experimental controls where appropriate.  
Ultimately comparison between separate western blots only occurred when evaluating the 
pilot samples and not in the main sample groups. This was due to variation in signal 
density between blots that was difficult to standardise. While attempts were made to 
introduce a constant/correction factor (×), in order to correct for blot variation, and allow 
inter-blot comparison, this technique ultimately was not pursued, as it was deemed 
imprecise. Thus, statistical comparisons were only made on data accrued within 
individual experiments, i.e. intra-blot comparison, rather than inter-blot comparison.   
Another option, to allow comparison between blots would have been to run known 
standard samples on each gel. Additionally, there could be the option of using computer 
software to correct for signal variance and exposure on each blot. These options were not 
pursued, as ultimately numerical values for CLU in the canine samples were generated 
via ELISA. 
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Numerical values for CLU concentrations were generated using a commercially available 
ELISA kit for canine CLU (BioVendor Ltd). Each sample on the ELISA plate was run in 
duplicate, with final results an average of the two sample values, this allowed for some 
pipetting error. Additionally, standard quality control (QC) samples were included with 
each individual ELISA run, with the predicted values provided for each kit. These 
provided an intra-assay control of the experimental technique itself, unrelated to sample 
quality or disease status. ELISA manufacturing data reports an intra-assay variance of 
4.3%, which gave confidence in the comparisons across individual experiments. 
Furthermore, with each ELISA run, the QC values matched the reported range and the 
standards generated an appropriate standard curve for the samples. In addition, the 
positive correlation between Western blot values (where CLU is visualised at the correct 
molecular weight) and ELISA protein concentrations provided strong evidence that the 
ELISA method was indeed detecting the CLU protein.  
Inter-assay comparison was also carried out, with the aim of allowing comparison of a 
larger number of samples. The ELISA plates should have generated reliable, and 
comparable data.  However, despite inter-assay variance reported at 6.2% (BioVendor) 
our own data showed a more marked discrepancy between samples run on separate 
ELISA plates. With coefficient of variance for individual samples ranging from 5.9-
19.4%, more in line with independent validation of the ELISA (García-Martínez et al., 
2012) which found inter-assay coefficient of variation to range from 14.2-16.1%, with 
higher concentrations found to be more variable, both on inter-assay and intra-assay 
validation. Canine serum CLU concentrations, as described in section 3.6.1, were 
significantly higher in samples run on ELISA plate three, in comparison to results from 
ELISA plate two, (Figure 19) with percentage increases in mean CLU concentrations 
ranging from 2% - 40.1%.  
Based on the ELISA kit information provided, regarding repeatability and comparability, 
this degree of variability between individual samples was unexpected. There were only a 
small number of samples available which were run on multiple ELISA plates, thus sample 
quality, sample handling and experimental technique, may have influenced these results. 
Each ELISA plate was run with individual master standards, used to generate a standard 
curve. An increase in CLU levels between the two ELISA plates may also have been due 
to standard variability.  
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Regardless of variability in results between different western blots or ELISA plates, the 
outcome of each experiment revealed the same results or trend towards results. Across 
multiple western blots, and ELISAs, the CLU levels in dogs with MLSA were 
consistently (although not always significantly) lower than those of healthy controls. This 
gives confidence, even if results were not directly comparable, or repeatable within a 5% 
variable, and carried a degree of imprecision. All data trends, regardless of technique 
used, show that CLU levels were lower in diseased samples. 
 
 Study limitations and considerations 
There are limitations associated with this study that merit discussion. Since the study was 
partly retrospective nature, many limitations resulted from reliance on patient records and 
previously collected, stored samples.  
Patient records were occasionally incomplete, and samples frequently lacked histological 
evaluation. Lack of histopathology limited MLSA classification beyond cytological grade 
and immunophenotype, meaning the sample group consisted of a relatively heterogenous 
population. Previous studies (Saffer et al., 2002) have shown variable CLU levels 
different subtypes of human lymphoid neoplasia. It is possible that different subtypes of 
canine LSA could have varying serum CLU levels, and the lack of precise classification 
could be limiting the understanding of CLU in canine MLSA.  
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While every precaution was taken to ensure the integrity of the cases and samples 
selected, there were multiple samples stored, at -80°C, for over a year. Previous studies 
of sample stability have shown no alteration in human CLU levels in plasma following 
>6 years stored at -80°C (Morgan et al., 2017), with storage of serum samples for up to a 
year also having no effect on CLU levels (Morrissey et al., 2001), although studies for 
stability in stored serum over longer periods of time were not found. As samples were 
selected from a bank of stored samples the exact freeze/thaw cycle history was not always 
known. However, previous studies have shown no change in CLU levels following five 
freeze/thaw cycles (Aguilar-Mahecha et al., 2009), a number which was not exceeded in 
the current investigations. Protocol for sample storage was to have samples stored frozen 
within 24 hours of collection, due to the retrospective nature of this study, it is not possible 
to know the history of every sample. This may be of importance, as although stable when 
frozen or refrigerated, a study of CLU stability in CSF (Shafie et al., 2013), showed CLU 
levels significantly reduced when incubated at room temperature for 48 hours.  
Additionally, the ELISA technique used showed a higher degree of inter-assay variability 
than expected from the manufacturer guidelines. Ideally samples would have been run 
across multiple ELISA plates, and repeated multiple times to ensure optimum technique 
and minimal variation. This was not possible due to a lack of various resources, including 
time, sample volume and finances, with each ELISA kit a considerable expense.  
As previously mentioned, it could not be excluded that the results of this study represent 
type I error, and rejection of a true null hypothesis due to a non-representative sample 
population. In addition, the small sample numbers could also be a limiting factor, 
representing a type II error particularly when evaluating the difference in CLU levels 
within the pre-treatment MLSA samples and between pre-treatment and CR samples. 
When evaluating power calculations, due to the wide individual variation CLU levels, 
sample groups of 400-500 would have been required to further assess statistical 
significance when comparing pre-treatment and CR MLSA samples.  
Due to the retrospective nature of the study, treatment of the MLSA cohorts was not 
standardised, other than the first 4-6 weeks of the CR cohort. Some patients did not pursue 
chemotherapy, others chose less intense/single agent regimes thus it was not appropriate 
to assess MST with regard to CLU levels or attempt to attribute prognostic value to pre-
treatment CLU levels.  
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These limitations are typical for a study of this nature that relies on the collection of 
material from cases over an extended period of time. However, when giving consideration 
to these factors, it can be concluded that that despite limitations, studies of this nature are 
important and have the potential to identify biomarkers that may prove to be of diagnostic 
and prognostic value. 
 
 Further research  
The significant variation in serum CLU levels suggests it is unlikely to be of use as a 
diagnostic biomarker. While not useful as a stand-alone biomarker, CLU may prove of 
use in combination with other, emerging or established markers. Investigation of larger 
sample cohorts could help to develop a reference range for CLU in the healthy adult dog, 
and aid in determining accurate and meaningful diagnostic cut off values for serum CLU. 
Additionally, expanding the MLSA sample population to a larger size would also allow 
better evaluation of CLU in relation to immunophenotype, stage and substage of MLSA 
and potentially enable evaluation of CLU as a prognostic biomarker.  
Larger cohorts would increase statistical power and reduce the likelihood of type II error. 
This would be of use particularly in the comparison of pre-treatment and CR samples, 
where alterations in serum CLU could prove predictive for remission or early relapse. 
Prospective assessment of serum CLU concentration, with standardised treatment 
protocols, would also enable evaluation of MST and prognostic value of pre or post 
treatment CLU levels. 
In addition, further investigations to evaluate the cytoplasmic CLU expression via IHC 
in canine MLSA tissue, in tandem with the circulating serum CLU levels, would be of 
interest. Establishing any association between circulating serum CLU levels and tissue 
CLU could help to clarify the relationship between CLU and canine MLSA and determine 
whether IHC could be of more value than serum analysis of CLU. 
Alternatively CLU has also been widely evaluated as a biomarker excreted in the urine 
(Aulitzky et al., 1992; García-Martínez et al., 2012; Fowlie et al., 2017). Evaluation of 
urinary CLU in canine MLSA patients has yet to be investigated but may hold potential 
as a non-invasive monitoring tool for detection of disease or early relapse.   
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 Complement component three (C3) 
During protein electrophoresis of the pilot samples an additional protein was noted, 
expressed preferentially in dogs with MLSA, in comparison to healthy controls. Since 
this could represent a potential MLSA biomarker, two protein bands were excised from 
the agarose gel and the protein content identified via mass spectrometry, (Appendix 5).   
Complement C3 was identified in both samples analysed, as determined by protein 
sequences to an established database. While likely to be raised in a variety of conditions, 
and not specific to canine MLSA, complement C3 was recognised as a potential marker 
and may warrant further investigation.  
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5 Conclusion 
In the current study, serum CLU was significantly lower in patients with MLSA, although 
significant individual variation existed. The repeatability and marked degree of individual 
variation, leading to a wide range of results within sample populations, suggests that 
serum CLU would have limited benefit as a stand-alone diagnostic biomarker, or marker 
of remission. However, the potential prognostic value of pre-treatment or post-treatment 
serum CLU has not been investigated. Additional studies, including concurrent 
immunohistochemical evaluation of CLU in lymph nodes/tissue, would be required to 
fully evaluate CLU expression in canine MLSA.  
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7 Appendices  
 Appendix 1 – Hospital consent form  
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 Appendix 2 – CHOP protocol 
WEEK DRUGS 
1 Vincristine 0.7mg/m2 IV 
Prednisolone 2mg/Kg or 40mg/m2 PO SID 
2 Cyclophosphamide 250mg/m2 PO 
Prednisolone 1.5mg/kg or 30mg/m2 PO SID 
Furosemide 1-2mg/Kg PO 
3 Vincristine 0.7mg/m2 IV 
Prednisolone 1mg/kg or 20mg/m2 PO SID 
4 Doxorubicin 30mg/m2 IV (+ 0.9% NaCl) 
Prednisolone 0.5mg/kg or 10mg/m2 PO SID 
Chlorphenamine 2-10mg total dose IM 
Maropitant 1mg/Kg SC 
6 Vincristine 0.7mg/m2 IV 
7 Cyclophosphamide 250mg/m2 PO 
Furosemide 1-2mg/Kg PO 
8 Vincristine 0.7mg/m2 IV 
9 Doxorubicin 30mg/m2 IV (+ 0.9% NaCl) 
Chlorphenamine 2-10mg total dose IM 
Maropitant 1mg/Kg SC 
11 Vincristine 0.7mg/m2 IV 
13 Cyclophosphamide 250mg/m2 PO/IV (+ NaCl) 
Furosemide 1-2mg/Kg PO 
15 Vincristine 0.7mg/m2 IV 
17 Doxorubicin 30mg/m2 IV (+ 0.9% NaCl) 
Chlorphenamine 2-10mg total dose IM 
Maropitant 1mg/Kg SC 
19 Vincristine 0.7mg/m2 IV 
21 Cyclophosphamide 250mg/m2 PO 
Furosemide 1-2mg/Kg PO 
23 Vincristine 0.7mg/m2 IV 
25 Doxorubicin 30mg/m2 IV (+ 0.9% NaCl) 
Chlorphenamine 2-10mg total dose IM 
Maropitant 1mg/Kg SC 
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 Appendix 3 - Sample Lists 
*indicates samples also used in pilot sample group 
 Control samples 
 Pilot study  
Sample number  Age(years) Breed Sex 
1 2 Flat-coated Retriever ME 
2 7 Labrador Retriever MN 
3 2 Golden Retriever MN 
4 7 Labrador Retriever FN 
5 0.75 German Shepherd  ME 
6 4 German Shepherd  ME 
7 2 Crossbreed MN 
8 5 Labrador Retriever MN 
9 7 Greyhound FN 
10 4 Doberman  FN 
11 1 Golden Retriever FE 
12 5 Golden Retriever FN 
13 1 Golden Retriever MN 
14 7 Springer Spaniel  MN 
15 5 Labrador Retriever FN 
16 4 Labrador Retriever FN 
17 4 Greyhound FN 
18 3 Labrador Retriever MN 
19 3 Labrador Retriever MN 
20 3 Labrador Retriever ME 
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 Sample Group One – Cohort C 
 
Sample number Age(years) Breed Sex 
C1* 2 Flat-coated Retriever ME 
C2* 7 Labrador Retriever MN 
C3* 2 Golden Retriever MN 
C4* 7 Labrador Retriever FN 
C5* 0.75 German Shepherd  ME 
C6* 4 German Shepherd  ME 
C7* 2 Crossbreed MN 
C8* 5 Labrador Retriever MN 
C9* 7 Greyhound FN 
C10* 4 Doberman  FN 
C11* 1 Golden Retriever FE 
C12* 5 Golden Retriever FN 
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 Sample Group Three – age matched samples  
 
Sample number  Age(years) Breed Sex 
Ec13 * 4 Labrador Retriever FN 
Ec14 * 4 Greyhound FN 
Ec15 4 Weimaraner ME 
Ec16 4 Labrador Retriever ME 
Ec17 4 Greyhound MN 
Ec18 * 5 Labrador Retriever FN 
Ec19 5 Greyhound FN 
Ec20 5 Greyhound MN 
Ec21 5 Crossbreed FN 
Ec22 5 Greyhound FN 
Ec23 5 Greyhound MN 
Ec24 5 Greyhound MN 
Ec25 6 Golden Retriever FN 
Ec26 6 Greyhound FN 
Ec27 * 7 Springer Spaniel  MN 
Ec28 7 Doberman  ME 
Ec29 7 Golden Retriever FN 
Ec30 7 Labrador Retriever ME 
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 MLSA pre-treatment samples  
 Pilot study   
Sample 
number  
Age 
(years) 
Breed Sex Stage Substage Immunophenotype 
1 7 Boxer MN III b - 
2 2 Cocker spaniel  ME III b - 
3 6 German shepherd  ME III a - 
4 6 Crossbreed ME V a B 
5 10 Border collie  ME V b B 
6 4 Tibetan terrier MN IV b B 
7 8 Springer spaniel ME III b T 
8 10 Crossbreed ME IV a B 
9 9 Cairn terrier  MN IV a - 
10 6 Border collie  ME IV b - 
11 10 Boxer MN V b B 
12 7 Airedale terrier MN III a - 
13 6 Bullmastiff FN IV b B 
14 12 Border collie  ME V b B 
15 3 Patterdale terrier FE V b - 
16 8 Labrador retriever FN IV a null 
17 3 Springer spaniel FN IV b - 
18 7 Gordon setter FE IV b T 
19 7 Boxer MN V b - 
20 10 Border terrier  ME V b B 
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 Sample Group One – cohort A 
 
Sample 
number 
Age 
(years) 
Breed Sex Stage Substage Immunophenotype 
A1* 10 Crossbreed ME IV a B 
A2* 9 Cairn terrier MN IV a - 
A3* 10 Border terrier ME V b B 
A4 6 Labrador retriever FE IV a B 
A5* 10 Border collie ME V b B 
A6* 10 Boxer MN V b B 
A7* 12 Border collie ME V b B 
A8 * 7 Boxer MN V b - 
A9 7 Labrador retriever MN V b - 
A10 5 Cavalier King 
Charles spaniel 
FE V b - 
A11 6 Border collie MN V b B 
A12 * 7 Gordon setter FE IV b T 
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 Sample Group Two – paired samples 
 
Sample 
number 
Age 
(years) 
     Breed Sex Stage Substage Immunophenotype 
D1 14 Parsons terrier ME V b - 
D2 11 Crossbreed FN III a - 
D3 6 Golden retriever FN V b T 
D4 3 Cocker spaniel ME V b T 
D5 5 Golden retriever ME III a B 
D6 10 Border collie FE IV b - 
D7 9 West Highland terrier FN IV a B 
D8 8 Golden retriever MN V a - 
D9 12 Yorkshire terrier FN IV a B 
D10 12 Border collie FN IV a B 
D11 9 Labrador retriever MN V b - 
D12 8 German shepherd ME V b B 
D13 5 Border collie MN IV a B 
D14 9 Shih tzu MN IV a B 
D15 9 Labrador retriever FN IV b B 
D16 6 Jack Russel terrier ME III a - 
D17 5 Tibetan terrier FN IV a B 
D18 10 Spinone FN IV a B 
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 Sample Group Three – age matched samples 
+    indicates samples also used in sample group two 
 
Sample 
number 
Age 
(years) 
Breed Sex Stage Substage Immunophenotype 
E1 3 Flat-coated retriever ME IV b B 
E2 4 Boxer FN IV b T 
E3 5 Bullmastiff FN III b T 
E4 5 Cocker spaniel  ME III b T 
E5 6 Golden retriever MN V b T 
E6 6 Bernese mountain 
dog 
MN IV b B 
E7 6 Shetland sheepdog MN III b T 
E8 6 Lurcher MN III a - 
E9 6 Crossbreed FN III a - 
E10 7 Border collie  MN IV a T 
E11 7 Dogue de Bordeaux MN IV b - 
E12 7 Border collie  MN IV b T 
E13+ 6 Golden retriever FN V b T 
E14+ 3 Cocker spaniel  ME V b T 
E15+ 5 Golden retriever ME III a B 
E16+ 5 Border collie  MN IV a B 
E17+ 6 Jack Russell terrier ME III a - 
E18+ 5 Tibetan terrier FN IV a B 
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 MLSA CR samples  
 Sample Group One – cohort B 
 
Sample 
number  
Age 
(years) 
Breed Sex Stage Substage Immunophenotype 
B1 10 Golden retriever FN IV b B 
B2 7 Crossbreed MN IV b - 
B3 12 Crossbreed MN IV b B 
B4 4 Jack Russel terrier FN III a B 
B5 12 Whippet MN V b B 
B6 8 Cocker spaniel  ME III a B 
B7 4 Hungarian vizsla ME III a B 
B8 5 German shepherd FN IV b B 
B9 8 Dachshund FN IV a B 
B10 9 Beagle  ME II b - 
B11 6 Border collie  MN V b B 
B12 5 Tibetan terrier FN IV a B 
 
 Sample group two - paired samples  
Samples from the same cohort in section 7.2.2.3, were also taken at time of CR, as 
determined by physical examination and lymph node palpation, at week 4-6 of a (CHOP-
based) chemotherapy protocol, by a qualified veterinary surgeon experienced in 
veterinary oncology.  
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 Appendix 4 – ELISA protocol 
  Serum sample preparation 
Mix thoroughly thawed samples just prior to the assay and avoid repeated freeze/thaw 
cycles and using haemolysed or lipemic samples.  
Serum samples: Dilute samples just prior to perform the test 2500x with Dilution Buffer 
in two steps as follows -  
Dilution A (50x): Add 5 l of sample into 245 l of Dilution Buffer and mix well (not 
to foam). Vortex is recommended.  
Dilution B (50x): Add 5 l of Dilution A into 245 l of Dilution Buffer to prepare final 
dilution 2 500x. Mix well (not to foam). Vortex is recommended.  
Stability and storage: Samples should be assayed immediately after collection or should 
be stored at -20°C, or preferably at -70°C for long-term storage.  
 
 Assay procedure   
1. Pipet 100 l of diluted standards, quality controls, dilution buffer and samples, into 
the appropriate wells, preferably in duplicate. 
2. Incubate the plate at room temperature (25°C) for 1 hour, at 300 rpm on an orbital 
microplate shaker.  
3. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, 
invert and tap the plate strongly against paper towel.  
4. Add 100 l of Biotin Labelled Antibody solution into each well.  
5. Incubate the plate at room temperature (25°C) for 1 hour, shaking at 300 rpm on an 
orbital microplate shaker.  
6. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, 
invert and tap the plate strongly against paper towel. 
 7. Add 100 l of Streptavidin-HRP Conjugate into each well. 
 8. Incubate the plate at room temperature (25°C) for 30 min, shaking at 300 rpm on an 
orbital microplate shaker. 
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 9. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, 
invert and tap the plate strongly against paper towel.  
10. Add 100 l of Substrate Solution into each well. Avoid exposing the microtiter plate 
to direct sunlight.  
11. Incubate the plate for 10 minutes at room temperature. The incubation time may be 
extended [up to 20 minutes] if the reaction temperature is below than 20°C. Do not 
shake the plate during the incubation.  
12. Stop the colour development by adding 100 l of Stop Solution. 
 13. Determine the absorbance of each well using a microplate reader set to 450 nm, 
preferably with the reference wavelength set to 630 nm (acceptable range: 550 – 650 
nm). Subtract readings at 630 nm (550 - 650 nm) from the readings at 450 nm. The 
absorbance should be read within 5 minutes following step 12.  
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 Appendix 5 - Mass Spectrometry for Complement 3 
Mascot Search Results 
Search title: Orbitrap NCBI Dog Search 
Database: NCBInr 20160830 (93482448 sequences; 34454162062 residues) 
Taxonomy: Canis lupus familiaris (Dog) (41680 sequences) 
Timestamp: 11 Jan 2017 at 10:52:42 GMT 
Enzyme: Trypsin 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Mass values: Monoisotopic 
Protein Mass: Unrestricted 
Peptide Mass Tolerance: ± 10 ppm (# 13C = 1) 
Fragment Mass Tolerance: ± 0.5 Da 
Max Missed Cleavages: 1 
Instrument type: ESI-FTICR 
Number of queries: 4178 
 
Protein hits with Mascot score >100 listed:   
gi|545535669 PREDICTED: complement C3 [Canis lupus familiaris] 
 Mass: 181723 Score:1564 Matches: 42(42) Sequences: 36(36) 
gi|545520919 PREDICTED: serum albumin isoform X1 [Canis lupus familiaris]  
 Mass: 70558 Score: 1538 Matches: 34(34) Sequences: 23(23) 
gi|55742764 serum albumin precursor [Canis lupus familiaris]  
 Mass: 70556 Score: 1277 Matches: 31(31) Sequences: 22(22) 
gi|123511 Haptoglobin alpha chain; Haptoglobin beta chain  
 Mass: 36890 Score: 868 Matches: 28(28) Sequences: 16(16) 
gi|75043394 Keratin, Cytokeratin-10 
 Mass: 57847 Score: 747 Matches: 14(14) Sequences: 10(10)  
gi|928167632 PREDICTED: serotransferrin [Canis lupus familiaris]  
 Mass: 80222 Score: 602 Matches: 14(14) Sequences: 13(13) 
gi|3915605 Apolipoprotein E 
 Mass: 35332 Score: 426 Matches: 8(8) Sequences: 7(7) 
gi|928150787 PREDICTED: complement C4-A [Canis lupus familiaris]  
 Mass: 199301 Score: 414 Matches: 10(10) Sequences: 9(9) 
gi|545552242 PREDICTED: complement factor I isoform X1 [Canis lupus familiaris]  
 Mass: 69506 Score: 366 Matches: 7(7) Sequences: 3(3) 
gi|3915607 Apolipoprotein A-I 
 Mass: 30178 Score: 346 Matches: 9(9) Sequences: 8(8) 
gi|50979272 keratin, type II cytoskeletal 1 [Canis lupus familiaris]  
 Mass: 63922 Score: 320 Matches: 7(7) Sequences: 6(6) 
gi|560879429 zinc-alpha-2-glycoprotein precursor [Canis lupus familiaris]  
 Mass: 36060 Score: 303 Matches: 6(6) Sequences: 6(6) 
gi|345791833 PREDICTED: keratin, type II cytoskeletal 3 [Canis lupus familiaris]  
 Mass: 62762 Score: 243 Matches: 4(4) Sequences: 4(4) 
gi|75062694 Keratin, type II cytoskeletal 2 epidermal  
 Mass: 64812 Score: 239 Matches: 6(6) Sequences: 5(5) 
gi|17066526 immunoglobulin gamma heavy chain B [Canis lupus familiaris]  
 Mass: 52553 Score: 228 Matches: 7(7) Sequences: 6(6) 
gi|345791904 PREDICTED: keratin, type II cytoskeletal 5 [Canis lupus familiaris]  
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 Mass: 63006 Score: 209 Matches: 4(4) Sequences: 4(4) 
gi|50979240 clusterin precursor [Canis lupus familiaris] 
  Mass: 52327 Score: 205 Matches: 4(4) Sequences: 4(4) 
gi|928172771 PREDICTED: Ig lambda chain V-I region BL2 isoform X1 [Canis lupus 
familiaris]  
 Mass: 25286 Score: 197 Matches: 4(4) Sequences: 3(3) 
gi|345791839 PREDICTED: keratin, type II cytoskeletal 6A isoform X2 [Canis lupus 
familiaris]  
 Mass: 63174 Score: 186 Matches: 4(4) Sequences: 4(4) 
gi|928186325 PREDICTED: inter-alpha-trypsin inhibitor heavy chain H4 isoform X1 
[Canis lupus familiaris] 
 Mass: 105582 Score: 169 Matches: 4(4) Sequences: 4(4) 
gi|73960685 PREDICTED: C4b-binding protein beta chain [Canis lupus familiaris]  
 Mass: 29379 Score: 163 Matches: 5(5) Sequences: 4(4)   
gi|545544683 PREDICTED: Ig lambda chain V-I region BL2 isoform X42 [Canis lupus 
familiaris]  
 Mass: 25081 Score: 149 Matches: 3(3) Sequences: 3(3) 
gi|345778397 PREDICTED: complement factor B [Canis lupus familiaris]  
 Mass: 87635 Score: 135 Matches: 3(3) Sequences: 3(3)  
gi|359279911 keratin 14 [Canis lupus familiaris]  
 Mass: 52621 Score: 129 Matches: 3(3) Sequences: 3(3) 
gi|73996461 PREDICTED: keratin, type II cytoskeletal 78 [Canis lupus familiaris]  
 Mass: 56429 Score: 118 Matches: 2(2) Sequences: 2(2)  
gi|73956164 PREDICTED: microfibril-associated glycoprotein 4 [Canis lupus 
familiaris]  
 Mass: 28775 Score: 117 Matches: 2(2) Sequences: 1(1) 
gi|545553759 PREDICTED: alpha-2-HS-glycoprotein [Canis lupus familiaris] 
 Mass: 40021 Score: 108 Matches: 1(1) Sequences: 1(1)  
gi|57106717 PREDICTED: keratin, type II cuticular Hb4 [Canis lupus familiaris]  
 Mass: 64358 Score: 101 Matches: 2(2) Sequences: 2(2) 
  
 
121 
 
 
 Appendix 6 – ROC curve for combined CLU data.  
 
 
 
ROC curve for serum CLU concentrations using combined data from MLSA pre-
treatment and control samples across three ELISA plates.  
Area under the ROC curve – 0.9063 
p<0.0001 
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